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Abstract 
 
 In order to generate and monitor effective and specific immune responses against tumors, 
a clear understanding of relevant tumor antigens and their derivative epitopes recognized by T 
lymphocytes is warranted.  The characterization of tumor antigen epitopes recognized by T 
lymphocytes has been a major focus of study over the past decade.  Both CD8+ and CD4+ T 
lymphocytes contribute to the immune response against tumors, and the determination of the 
epitopes they recognize is necessary for their incorporation into immunotherapy protocols for 
cancer.  The tumor antigens recognized by T lymphocytes fall into 3 major categories:  Tumor-
specific (TSA), Cancer Testis (CT), and Tumor Associated Antigens (TAA).  Our goal in the 
following studies was to characterize a novel TAA, EphA2, since this protein has been linked to 
metastasis in numerous cancer settings. 
The definition of epitopes seen by T lymphocytes will assist in vaccine strategies for 
immunotherapy protocols against EphA2+ tumors.  In the following studies, I have defined 8 
novel EphA2 T cell epitopes (5 HLA-A2 restricted and 3 HLA-DR4 restricted) recognized by 
CD8+ and CD4+ T lymphocytes, respectively.  The anti-EphA2 CD4+ functional response was 
skewed based on the presence of disease or increased staging of RCC disease, with patients with 
active disease exhibiting a Th2-biased CD4+ response.  I have also linked the expression of 
EphA2 in primary RCC tumors to the time to recurrence in patients affected with RCC.  
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Furthermore, I have demonstrated that the cell surface expression of EphA2 on tumors can be 
modulated using EphA2 agonists.  This agonist treatment results in the enhanced recognition of 
EphA2+ tumors by specific CTLs.  With reports of the overexpression of protein phosphatases 
(PPs) in several cancer settings, we discovered the EphA2 was constitutively 
underphosphorylated in certain cancer cell lines, likely as the consequence of overexpressed PP 
activity.  Finally, I have shown that by neutralizing the activity of cellular phosphatases utilizing 
phosphatase inhibitors, that we can induce the phosphorylation of EphA2 and its subsequent 
degradation via a largely proteasome-dependent pathway.  As a result, this thesis has defined a 
novel tumor antigen, EphA2, and demonstrated the possibility that modulation of its expression 
in tumor cells may result in increased recognition by specific T effector cells that may be 
germane to the design of improved and efficacious therapies for the treatment of patients with 
EphA2+ tumors. 
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1. INTRODUCTION 
 The Eph family of molecules contains 14 members, comprising the largest known cohort 
of receptor tyrosine kinases (RTK) (1).  Based on sequence similarity and binding affinities, two 
classes of receptors have been defined, EphA and EphB.  There are 8 members of the EphA 
receptor family (EphA1 – EphA8) that primarily bind 5 ephrin-A ligands (ephrinA-1 – ephrinA-
5).  Ephrin-A ligands are attached to the cell surface via glycosylphosphotidylinositol (GPI) 
anchors and tend to bind only EphA receptors.  There are 6 members of the EphB receptor 
family (EphB1 – EphB6).  The EphB receptors primarily bind 3 ephrin-B ligands (ephrinB1 – 
ephrinB3) which are transmembrane proteins.  However, Eph-ephrin binding is promiscuous in 
some respects, as there is some crossover between Eph receptors and ephrin ligands.  Similarly 
to other RTK, Eph receptors are type 1 transmembrane proteins (2).  The extracellular N-
terminus consists of a highly conserved ligand binding region, followed by a cysteine-rich 
region, and two membrane-proximal fibronectin Type-III repeats (Figure 1).  The intracellular 
region of Eph receptors starts with a juxtamembrane segment with contains two major auto-
phosphorylation sites, followed by a conserved kinase domain, which phosphorylates secondary 
adapter proteins and can phosphorylate the Eph receptors themselves (3).  The most C-terminal 
region contains a sterile a motif (SAM), and a PDZ binding domain.  The PDZ domain may be 
involved in receptor oligomerization (4), facilitating the binding of adapter proteins , or 
mediating receptor dimerization (5).  The binding of Eph receptors to their ephrin ligands occurs 
at a 1:1 stoichiometric ratio, with the complex forming a circularized heterotetramer (6). 
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1.1. Eph:Ephrin Signaling 
The sequence of signals that are propagated when ephrins and Eph receptors interact has 
been studied extensively over the past several years.  In their inactive conformations, Eph 
receptors contain an inhibitory loop in the juxtamembrane segment that inhibits the kinase 
domain.  Upon binding their respective ligands, two key tyrosine residues in the juxtamembrane 
region are phosphorylated, which allows for the kinase domain of Eph receptors to adopt their 
active conformation (7).  Up to 10 tyrosine residues in an Eph receptor are phosphorylated upon 
ligand binding (8).  These provide docking sites for secondary messenger molecules containing 
SH2 domains to associate with the newly phosphorylated tyrosines on Eph receptors.  Signaling 
between Eph receptors and ephrin ligands is bi-directional.  Upon binding its Eph receptor, 
ephrin-B ligands become phosphorylated on tyrosine residues (9).  This allows for the 
consequent association of Grb4, a SH2 containing secondary messenger, which has been shown 
to play a role in cytoskeletal regulation (10).  Similar to Eph receptors, ephrin-B ligands also 
contain a PDZ binding domain, that upon tyrosine phosphorylation provides a molecular 
framework for the construction of larger multi-molecular complexes (11).  Upon binding their 
respective receptors, ephrin-A ligands activate the mitogen associated protein kinase (MAPK) 
pathway, resulting in alterations in cellular structure and adhesive properties (12).  Although 
their interaction results in the activation of erk-1, which is associated with cellular proliferation, 
the binding of Eph receptors to ephrins does not necessarily promote cell proliferation and 
differentiation (13). In fact, certain evidence suggests that signaling either indirectly or directly 
through Eph receptors may actually suppress cell growth. 
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1.2. Eph Receptors and Development 
Eph receptors were originally defined through their involvement in various embryonic 
developmental processes and tissue formation pathways.  Antagonism (blocking) of the 
interaction of Eph receptors and ephrin-B ligands in the developing presomitic mesoderm in 
Zebrafish results in the improper formation of somatic boundaries (14).  These interactions are 
also important in mediating axon guidance, regulating and directing nascent nerve networks 
during development (15).  In Xenopus embryos, EphA4 and EphB4 in addition with ephrin-B2, 
are involved in developing the boundary between the third-arch neural crest cells and the second 
branchial arch.  Eph receptors also play a role in the development of tissue “topography” based 
on gradients of Eph/ephrin expression (16).  EphA3 and EphA4, along with ephrin-A2 and 
ephrin-A5, in particular, are involved in the developmental guidance of axons that attach the 
retina to the tectum (17) in the eye. 
The organization of the vascular system is yet another area where the Eph/ephrins system 
plays a vital role during development.  The mRNA for ephrin-A1 is detected in multiple 
developmental vascular tissues, including the limb buds, the dorsal aorta, and primary head veins 
in mice (18, 19).  Both ephrin-B2 and EphB4 are expressed predominantly on the murine venous 
endothelium (20).  If either of these genes are knocked out, mid-gestational lethality and major 
vascular defects are observed in the mouse embryo (21, 22), demonstrating the importance of 
these molecules in mammalian development.  In vitro, the addition of ephrin-B2 and ephrin-B1 
induces angiogenic vessel sprouting as efficiently as either VEGF or angiopoetin-1 (21).  Finally, 
the Eph/ephrin system has also been reported to play a key role in the developing cardiac 
vasculature as well.  EphB2, EphB4, and ephrin-B2 are expressed in the embryonic cardiac 
tissue, suggesting they play key roles in the developing embryo (21, 22). 
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1.3. Eph Receptors and Cytoskeleton 
The developing embryo is not the only area where the Eph/ephrin system exerts its 
biologic influence.  Eph/ephrin binding and subsequent signaling has been found to induce 
processes that modify the cytoskeleton of affected cells.  This occurs via the recruitment and/or 
activation of signaling proteins directly involved in cytoskeletal reorganization.  (23-27).  EphB2 
when activated can phosphorylate R-Ras, which inhibits the ability of R-Ras to mediate integrin 
signaling (28).  EphB2 and EphB3 have been found to play a role in the migration of epithelial 
cells in the crypt/villus in the colon (29).  When these genes are knocked out in mice, the 
structure of the intestinal epithelium is disrupted and does not form properly. 
  
1.4. EphA2 Background 
One Eph receptor, EphA2, is of particular interest due to recent evidence suggesting it 
may play a role in the development and progression of cancer.  The EphA2 gene is located on 
human chromosome 1, and encodes a 130kDa (Type-1) glyco-protein that is expressed at low 
levels on numerous epithelial tissues (30).  Along with other Eph/ephrin family members, EphA2 
is involved in the organization of the developing nervous system (31) and vasculature (32), and 
is even expressed in embryonic stem cells (33).  In normal adult tissues, EphA2 is localized at 
epithelial cell-to-cell contacts, and is believed to play a role in contact inhibition (34).  This 
function involves inhibiting the growth of epithelial cells while they are in contact with other 
cells, and is critical for the organization and formation of epithelial layers in EphA2+ tissues.  
Activation of EphA2 results in the de-phosphorylation of focal adhesion kinase (FAK), which in 
turn suppresses integrin function (35).  EphA2 expression appears to be regulated by E-cadherin 
(36, 37).  A major protein involved in cell adhesion, E-cadherin is expressed in embryonic and 
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virtually all adult epithelial cells (38).  E-cadherin is dependent on Ca+2 binding for proper 
function, and is located at the adherens junctions between cells (39).  When E-cadherin 
expression and its phosphorylation is down-regulated via improper cytoplasmic expression, 
EphA2 protein expression becomes increased and its cellular localization is disrupted (36)  This 
demonstrates a key inverse relationship between these two proteins that may major roles in 
cellular adhesion. 
 
1.5. EphA2 and Cancer 
The role of RTKs and in carcinogenesis have been increasingly characterized over the 
last decade (Table 1)(40-55).  In particular, growing attention has been given to EphA2 in 
carcinogenesis with research demonstrating that EphA2 is correlated with the progression to 
metastasis.  Metastasis is the process whereby cancerous cells leave their tissue of origin; invade 
the extracellular matrix and traffick via either the lymphatics or the bloodstream to distal tissue 
sites. Metastatic disease is the most advanced and deadly type of cancer as it tends to be lethal 
and is extremely hard to treat.   
EphA2 protein has been reported to be overexpressed 10-100 times greater in metastatic 
prostate carcinoma cells when compared to non-invasive prostate epithelial cells (56).  EphA2 
protein is also expressed in greater amounts in malignant mammary tissue when compared to 
benign mammary epithelia (57, 58). Zelinski, et. al. have further reported that forced 
overexpression of EphA2 via transfection was sufficient to confer malignant transformation on 
MCF-10, a benign human mammary epithelial cell line.  In melanoma, EphA2 is vastly 
overexpressed in aggressive MUM-2B melanoma cells when compared to poorly invasive 
MUM-2C melanoma cells (59).  PANC1, a poorly differentiated pancreatic adenocarcinoma that 
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is highly invasive, overexpresses EphA2 when compared to the non-invasive Capan-2 pancreatic 
cancer cell line (60).  Given this evidence demonstrating the association of EphA2 
overexpression and dysregulation with carcinogenesis, along with its correlation with metastasis, 
one would predict that the degree and distribution of EphA2 protein expression in primary 
tumors may prove predictive of clinical outcome in patients with EphA2+ tumors. 
 
1.6. Mechanism of EphA2 Overexpression 
The mechanism by which EphA2 is over-expressed and consequently promotes 
metastasis has not yet been conclusively elucidated.  Several different possibilities impacting 
cellular expression of EphA2 include: gene amplification, decreased rates of protein degradation, 
and increased or stabilized mRNA transcription/translation.  An attractive current hypothesis 
associated with EphA2 over-expression by tumor cells involves the disruption of EphA2 
homeostatic protein degradation (Figure 2). 
In order to mediate proper signaling, EphA2 needs to bind its corresponding ligand on 
adjacent epithelial cells and in the cancer setting, this ability appears to be disrupted.  
Additionally, in EphA2+ tumors that lose expression of E-cadherin, EphA2 expression is 
increased and it is no longer found at sites of cell-to-cell contact, but in a perinuclear location 
(36).  When this occurs, EphA2 is no longer found at cell-to-cell contacts, exists in a non-
phosphorylated (inactive) state, and instead adopts a diffuse expression pattern throughout the 
cell. As a result, cell-to-cell contacts become weakened and cell-to-ECM attachments are 
enhanced (61).  This theory has been strengthened by the finding that the addition of exogenous 
ligand can restore appropriate tyrosine phosphorylation of EphA2 in tumor cells (62).  
Consequently, ubiquitin-dependent EphA2 protein degradation is enhanced; normalized EphA2 
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“metabolism” is restored and metastatic characteristics, including decreased ECM attachments, 
decreased motility, and increased cell-to-cell adhesions result.  Therefore, the dysregulated over-
expression of EphA2 may represent a first critical step in the progression to metastasis. 
 
1.7. EphA2 and Tyrosine Phosphorylation 
Upon ligand stimulation, autophosphorylation of the EphA2 receptor occurs which 
promotes the association of EphA2 with c-Cbl (62).  C-cbl contains an internal SH2 domain, 
which allows for it to bind to phosphorylated RTKs (63).  It also contains an ubiquitin E3-ligase 
which is responsible for the addition of ubiquitin molecules in order to target proteins for 
degradation via the proteasome and/or for sorting within the endocytic/lysosomal pathway (64).  
This is a major pathway in the recycling of RTK after they have signaled as a consequence of 
engaging their ligands.  In this pathway, internalized, activated EphA2 molecules that become 
de-phosphorylated are recycled to the cell membrane, while those that remain phosphorylated 
undergo proteasome-dependent degradation (65). 
As a consequence, cellular phosphatases play major regulatory roles in dictating the 
cellular fate of activated RTK.  In particular, protein tyrosine phosphatases (PTP) are responsible 
for the removal of phosphate groups added to RTK when they have been appropriately triggered 
by binding their respective ligands (66).  Of these, the low molecular weight-protein tyrosine 
phosphatase (LMW-PTP) has been reported to play a major role in acting on phospho-EphA2 
(pEphA2) as a substrate (67).  Under normal conditions, LMW-PTP removes the phosphate 
groups on tyrosine residues that are added to RTKs upon ligand stimulation (68, 69).  This 
removal of phosphate groups is necessary for the regulation of secondary signals that are 
generated upon ligand binding to RTKs.  However, the balance of phosphotyrosine content is 
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critical.  In order for RTKs to be properly recycled, they need to be phosphorylated.  Any 
disruption of this process could lead to an accumulation of RTKs on the surface of the cells that 
express them.  Recently, it has been reported that LMW-PTP is overexpressed in several cancers 
(70), giving credibility to its possible role in mediating tumor growth by dysregulating RTK 
expression/function.  This hypothesis has been further supported that low molecular weight-
protein tyrosine phosphatase (LMW-PTP) serves as an EphA2 PTP, and when overexpressed, 
LMW-PTP is sufficient to transform normal epithelial cells in vitro (67).  Overexpression of 
LMW-PTP decreases the phosphotyrosine content of EphA2 and likely plays a role in enhancing 
the stability and overexpression of EphA2 in cancer cells.  The increased stability of EphA2 on 
the surface of tumor cells may be an additional mechanism through which EphA2+ cancers 
acquire metastatic capabilities.  
 
1.8. EphA2 and Angiogenesis 
  As tumors increase in size, they require more nutrients and oxygen for their continued 
and sustained growth.  The inability of tumors to gain access to a new blood supply puts the 
tumor at risk of reaching a growth maxima, above which anoxia and necrosis are likely to occur. 
Tumors can create a neovasculature system using a process called angiogenesis that will provide 
them the necessary nutritional requirements that are needed for progressive growth (71).  
Establishment of neovessels also provides primary solid tumors portals through which they may 
metastasize and eventually colonize distant sites. Indeed, neoangiogenesis, the process in which 
new blood vessels are created from the existing vasculature, has been correlated with metastasis 
and poor prognosis in several cancers, including breast and pancreatic carcinomas (72, 73).  
Many different factors, including EphA2 and its ligands, are implicated in the process of 
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angiogenesis.  EphA2, along with one its ligands ephrin-A1, are expressed in growing neovessels 
of breast and sarcoma tumors (74).  Soluble EphA2 receptors have been found to inhibit VEGF-
mediated angiogenesis (75), and can successfully serve as antagonists in inhibiting tumor 
angiogenesis and growth in several animal models, including pancreatic cancer (76, 77) and 
melanoma (78).  This additional role for EphA2 in the angiogenesis process further strengthens 
the argument that EphA2 is a key player in the functional promotion of metastasis in situ.  
Indeed, along with its proposed roles in maintaining cell-to-cell contacts and inhibiting integrin 
function, the overexpression of EphA2 protein and dysregulation of its signaling implicate 
EphA2 as a major oncogenic factor. 
 
1.9. Cancer Overview 
Approximately 1,368,030 people in the United States will be diagnosed with some form 
of cancer along with approximately 563,000 that will die from cancer in the year 2004.  There 
are many biological processes where cells need to grow and expand (e.g. wound healing), 
however cancer arises when the checkpoints that cells employ to regulate their growth are 
disrupted.  Cancer is believed to starts out as a local, clonal outgrowth of cells.  As the primary 
tumor continues to successfully grow in its original location, it necessarily promotes the process 
of neo-angiogenesis that is required to provide a supportive blood supply carrying oxygen and 
nutrients.  Some tumors acquire the ability to leave their original location and colonize distant 
sites in the body, a process called metastasis.  Once this process has occurred, cancer becomes 
increasingly difficult to treat and has an increased mortality.  Historically, there have been three 
major traditional modalities for the clinical management of cancer: surgery, radiation, and 
chemotherapy.  Surgery is the process where the existing tumor is physically removed from the 
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body.  Radiation therapy is another method clinicians have used to battle cancer.  Considered a 
local treatment, radio-therapy involves using various forms of radiation to cause DNA damage to 
cancer cells or the supportive vascular bed, forcing these tissues to undergo apoptosis and to 
shrink in size.  Chemotherapy is the last of the three major therapies utilized against cancer.  
Chemotherapy involves the administration of chemicals that preferentially inhibit the ability of 
cancer cells to survive and replicate.  These drugs are generally applied systemically, and can be 
taken either in the form of a pill, or by injections provided s.c. or i.v.  These three methods have 
proved useful in many situations and have saved many lives, although their long-term efficacy is 
generally perceived as limited, with recurrent disease frequently found to be refractory to the 
original treatment modality. 
 
1.10. Immunotherapy Basics 
One of the more recent types of therapies that have been utilized to treat cancer is 
immunotherapy.  Immunotherapy involves using various components of the immune system to 
treat cancer.  The first evidence suggesting that manipulation of the immune system of cancer 
patients could be beneficial towards treating cancer involved the administration of interleukin-2 
(IL-2) (79).  IL-2 is a cytokine that is produced by T-cells that has the ability to induce 
proliferation of T cells that have recognized their specific antigen (80).  The administration of 
IL-2 in patients with metastatic renal carcinoma or metastatic melanoma was able to induce 
clinical regression at a rate of 15-20%.  These findings demonstrate that immunotherapy may 
hold promise, given that relative success noted for cytokine-based therapies and the anticipation 
that combinational immunotherapy approaches may further enhance the frequencies for objective 
clinical responses in prospective clinical trials. 
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One of the focal points of cancer immunotherapy has been in activating and sustaining 
the cell-mediated arm of the anti-tumor immune system, with the majority of attention being 
directed towards to tumor-specific T-lymphocytes. T-lymphocytes are divided into two primary 
groups based on their expression of a cell surface molecule that aids in their binding to human 
leukocyte antigen (HLA) molecules. Termed CD8+ or CD4+ T cells, both sets of T-lymphocytes 
recognize antigens that are presented to them via HLA molecules.  CD4+ T-lymphocytes 
recognize antigens presented by HLA Class II proteins, while CD8+ T-lymphocytes typically 
recognize tumor antigens in the context (as peptides that bind) of HLA Class I molecules. 
 
1.11. HLA Class I Antigen Processing 
HLA Class I proteins are highly polymorphic and form non-covalent, heterotrimeric 
complexes with the non-MHC encoded β2-microglobulin “light chain” and short peptides 
derived from intracellular degradative pathways.  Such complexes are presented to, and 
recognized by, CD8+ T cells (81).  These complexes are assembled in the ER as the culmination 
of a series of sequential protein-protein interactions, the first of which is the cotranslational 
insertion of class I “heavy chain” (i.e. α-chain) containing three Ig-like domains into the 
endoplasmic reticulum (ER; (82).  This chain is bound in the ER by calnexin until it associates 
with ß2-microglobulin (83).  The addition of ß2-microglobulin promotes the disassociation of 
calnexin, and the HLA- ß2-microglobulin complex is then bound by the ER chaperones 
calreticulin and tapasin (83).  These proteins retain the HLA/ß2-microglobulin complex in the 
ER until it becomes bound by a peptide with sufficient affinity for the class I binding groove, 
ensuring sufficient stability with the HLA/ß2-microglobulin complex to allow for transport of 
such complexes to the cell surface where they may be recognized by T cells (84).  Peptides that 
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bind HLA Class I proteins are actively transported into the ER by the transporter of antigenic 
peptides (TAP) in an ATP (energy)-dependent process (85).  HLA Class I molecules bind 
peptides of approximately 8-10 amino acids in length, and are primarily derived from 
endogenous proteins that have been degraded by the 26S proteasome (86, 87).  Upon entrance 
into the ER, peptides are then loaded onto HLA Class I molecules.  This allows for the 
disassociation of the HLA/ß2-microglobulin/peptide complex from the tapasin and calreticulin 
chaperones.  From this point, the HLA/peptide trimeric complex is transported through the Golgi 
apparatus to the cells surface for presentation to CD8+ T cells.  Similar to CD4+ Th cells, CD8+ 
T cells recognize peptides bound to HLA proteins via their TCR.  The cell surface molecule CD8 
binds to the α3 domain of the HLA protein, which stabilizes and “restricts” the interaction of the 
CD8+ T cell TCR with HLA class I molecules. 
 
1.11.1. 26S proteasome and degradation of cellular proteins 
When proteins become tagged with the polypeptide ubiquitin, they may become targeted to 
the proteasome for degradation (88).  The 26S proteasome is a 2000 kiloDalton (kDa) multimeric 
complex responsible for intracellular protein turnover (89, 90).  It is composed of 2 major 
subunits:  the 19S regulatory complex and the 20S core particle.  The 20S core is made up of 28 
subunits and is arranged in 4 stacked rings (91).  Within these subunits are active enzymatic sites 
for proteolytic degradation.  The conformational structure of the intact proteasome is crucial, 
given that when these proteolytic subunits are isolated individually, they lack protease activity 
(87).  Overall, these subunits display 3 types of peptidase activity. The first, type of specificity is 
“chymotrypsin-like” due to preferential cleavage of peptide sequences after large hydrophobic 
residues.  The second is a “trypsin-like” activity; i.e. cleavage of peptide sequences after basic 
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residues.  Lastly, a “caspase-like” activity has been reported that mediates cleavage after acidic 
amino acid residues. 
Two 19S regulatory complexes cap both ends of the 20S proteasome.  The 19S regulatory 
complex is made up of approximately 20 subunits and is 700-kD in size (87).  This complex 
enhances the peptidase activity of the 20S core complex, and is able to bind ubiquitinated 
proteins, thereby facilitating the funneling of proteins into the 20S core catalytic particle.  Upon 
insertion into the active proteasome, protein substrates are broken down in short, polypeptides 
that range in length from 4 to 24 residues. 
1.12. HLA Class II Antigen Processing 
Traditionally known as T-helper (Th) cells, CD4+ T-lymphocytes recognize antigens 
presented by HLA Class II proteins via their clonotypic T cell receptors (TCR) (92).  The TCR 
contains complementary determining regions (CDR) that bind to the HLA Class II proteins to 
facilitate the recognition of antigens by Th cells.  This interaction is stabilized by the T cell 
surface molecule CD4, which binds to the ß2 region of the HLA Class II protein.  HLA Class II 
proteins are heterotrimeric in structure, consisting of one monomorphic α-chain, one 
polymorphic ß-chain and one antigenic peptide.  Both the α and β chains contain two Ig-like 
domains, dimerize to form a peptide-binding groove, and are responsible for presenting peptides 
to CD4+ Th cells.  HLA Class II proteins are assembled in the endoplasmic reticulum (ER), and 
interact with the invariant chain (Ii), a protein which occupies the binding groove of HLA Class 
II proteins in this cellular compartment (93).  This prevents “premature” HLA loading of Class II 
α/β dimers with autologous antigenic peptides.  From the ER, Class II complexes are selectively 
targeted to compartments called MIIC by protein sequence sorting motifs located in the 
cytoplasmic domain of the co-associated Ii chain.  During its journey to the MIIC compartment, 
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the Ii chain bound to HLA Class II is trimmed down to yield class II-associated Ii-chain peptides 
(CLIP) (93).  The peptides CD4+ Th cells recognize are processed by the endocytic pathway of 
antigen processing.  Exogenous antigens are internalized by antigen presenting cells (APC) into 
endosomal vesicles (92).  These endosomes then fuse with the specialized lysosomal 
compartment MIIC, where exogenous antigens are broken down into short peptides.  Upon 
fusion of the antigen containing endosome and MIIC, the molecule HLA-DM removes CLIP, 
and edits HLA Class II binding peptides generated from exogenous antigens to ensure the 
stability of HLA Class II protein.  These peptides are approximately 15-20 amino acids in length.  
Once loaded, HLA Class II molecules are transported to the cell surface for presentation to 
CD4+ Th cells.  CD4+ T lymphocytes recognize antigens via their T cell receptor (TCR)  
 
1.13. Tumor Antigens 
Many biological changes that cancerous cells undergo result in the expression of tumor 
antigens.  Some of the antigens enhance the tumorigenicity of cancer, where others become 
expressed as a result of carcinogenesis, but may play no critical and beneficial role in the 
developing tumor microenvironment.  Most “clinically interesting” tumor antigens are proteins 
that tumor cells express abnormally and can be potentially targeted by the immune system.  
There are three major classes of tumors antigens: cancer testis (CT) antigens, tumor specific 
antigens (TSA), and tumor associated antigens (TAA).  During the course of carcinogenesis, 
many types of cancer undergo de-differentiation, that is, they revert to an earlier differentiative 
form of tissue (94, 95).  During this process, proteins that are not expressed in adult somatic 
tissues are now present in these cancerous cells.  The CT family of tumor antigens are normally 
expressed in fetal testicular tissue during development (96), and have been extensively 
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characterized and utilized for cancer immunotherapy studies (97-99).  Members of this family 
include GAGE, RAGE, and MAGE (100).  Tumor specific antigens are proteins that are only 
expressed on a specific tumor type and no others, with arguably the best examples being the 
clonotypic BCR and TCR expressed by B and T cell leukemias/lymphomas, respectively.  While 
less prototypical, gp100, MART-1, and tyrosinase are also three such antigens that are expressed 
only on melanoma and each encodes T cell epitopes that have been defined and used in 
immunotherapeutic vaccine protocols (100).  Tumor Associated Antigens (TAA) are typically 
proteins that are expressed on a wide range of tumors.  They are not specific with regard to the 
histology of cancer and are the most common type of tumor antigen.  In many cases, TAA are 
expressed by both normal tissues and cancer cells, although cancer cells may overexpress these 
proteins (vs. normal tissues) resulting in differential recognition by specific T cells. Given 
normal cell expression of these antigens and both central and peripheral tolerance mechanisms, 
TAA-specific T cells are commonly of moderate-to-low avidity to avoid autoimmune pathology. 
 
1.14. CD8+ T Cell-Mediated Immunity 
Based on decades of in vivo animal modeling and recent vaccine trials in humans, it is 
believed that in order for tumors to be rejected by the immune system a tumor-specific CD8+ T 
lymphocyte response must be promoted and sustained in treated patients with cancer.  Such 
responses appear best initiated through a process termed “cross-presentation”, in which host 
antigen presenting cells (APCs) acquire exogenous tumor antigens from dead or dying tumor 
cells and after processing, present these to CD8+ T cells (101).  Alternatively, specific CD8+ T 
cells may encounter MHC class I peptide complexes that are directly presented by the tumor cell. 
Upon recognition of their specific peptide, anti-tumor CD8+ T cells undergo several hallmark 
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responses.  They undergo a developmental transformation to become effector cytotoxic T 
lymphocytes (CTL) and acquire the ability to kill their target cells after specific antigen 
recognition (102).  They may also secrete important pro-inflammatory cytokines (i.e. γ-interferon 
(γ-IFN) and TNF-α) in response to specific TCR stimulation. 
CTL are able to kill target cells they recognize through several different mechanisms.  
Upon antigen recognition of a potential target cell, CTL may secrete perforin and/or granulysin, 
both of which are stored in pre-formed cytoplasmic granules of the CTL and aid in the killing of 
target cells.  Monomers of perforin are secreted from CTL and then insert themselves into the 
plasma membrane of target cells, aggregate to form a pore, and allow for other apoptosis-
mediating factors to enter the tumor cell more effectively (103).  Granulysin is a membrane 
perturbing polypeptide that most likely aids in the delivery of the cytotoxic mediators of CD8+ T 
cell-mediated immunity (104).  The major family of proteins that mediate CTL induced 
apoptosis are granzymes of which granzyme-B has been reported to be the most potent (105).  
Granzymes are serine proteases that induce apoptosis of targets cells via several mechanisms.  
Granzyme B is able to stimulate the caspase pathway of apoptosis with its ability to cleave 
procaspase-3.  This results in the formation of mature caspase-3, which in turn mediates the 
degradation of iCAD (inhibitor of caspase-activated DNase).  No longer bound by iCAD, CAD 
is then free to induce DNA fragmentation which ultimately results in the induction of apoptosis 
and cellular death (106).  In addition to caspase-3 activation, Granzyme B is also able to alter the 
membrane integrity of mitochondrial in a caspase-3 independent mechanism (107).  Granzyme B 
binds BID (BH3 interacting death domain), which results in the production of tBID (truncated 
BID).  tBID is then able to disrupt the outer membrane integrity of mitochondria.  This results in 
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the release of several pro-apoptotic factors from mitochondria, including cytochrome C, 
endonuclease G, and Htr2/OMI, all of which aid in the promotion of apoptosis.   
The tumor necrosis factor (TNF) receptor gene superfamily represents an additional 
pathway through which CTL are able to induce the death of their target cells.  Although all 
TNFR family members vary in primary sequence, they all contain a homologous intracellular 
sequence called a death domain (108).  Perhaps the most well-known receptor/ligand pair in this 
family is Fas and FasL (CD95/CD178).  When the TCR of CTL are engaged and activated by 
interactions with HLA Class I proteins, the T cells upregulate their expression level of FasL 
(109).  FasL is a homotrimeric protein that binds to 3 Fas receptors on CTL target cells (110).  
Upon binding, the death domains of the 3 Fas receptors are clustered and recruit pro-apoptotic 
adaptor proteins (e.g. FADD) via interactions with the death domains on the adaptor proteins   
The secondary adaptor proteins then are able to induce apoptosis in a caspase-8 dependent 
manner (111). 
 
1.14.1. Immunoregulatory Actions of γ-IFN 
γ-IFN is perhaps the hallmark cytokine of “clinically preferred” cell-mediated immunity.  γ-
IFN induces several key changes in the cells to which it binds and activates.  First, it is able to 
induce an increase in the surface expression of HLA molecules on treated target cells (112), in 
many cases making them more easily recognized by specific CD8+ T cells.  Secondly, γ-IFN 
induces the expression of several conditional proteasomal subunits:  LMP2, LMP7, and MECL-1 
(113).  These subunits alter protease activity in the proteasome so that the peptides generated are 
more likely to bind HLA Class I molecules.  Thirdly, γ-IFN is able to induce the expression of 
PA-28, a proteasome activator that is able to increase the proteolytic efficiency of the 20S 
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proteasome (114).  Other additional immunoregulatory effects of γ-IFN include, but are not 
limited to, increases in TAP, ß2-microglobulin, and tapasin expression by treated cells.  All of 
these proteins are involved in enhancing HLA Class I antigen processing and increase the 
efficiency of CD8+ T cell mediated immunity. 
 
1.15. CD4+ T Cell-Mediated Immunity 
Traditionally known as T-helper (Th) cells, CD4+ lymphocytes are believed to exert their 
influence on the adaptive immune response primarily by secreting cytokines in response to 
antigen recognition.  Cytokines are secreted proteins that have many immunomodulating effects 
on the cells they interact with.  The types of cytokines that CD4+ Th cells secrete allows for 
them to be functionally discriminated into three major groups; namely Th1, Th2, and 
Th3/Tregulatory (Treg) (115).  A Th1-type cytokine profile involves Th production of the 
cytokines γ-IFN and IL-2 (116), with both of these cytokines known to promote the cell-
mediated arm of the immune system.  γ-IFN and IL-2 upregulate HLA expression (112, 117, 
118), promote CTL proliferation and differentiation, enhance HLA Class I antigen processing, 
and suppress Th2-type immune responses that may be sub-optimal to the regulation of cancer in 
situ.  A Th2-type cytokine profile includes the production of IL-4, IL-5 and IL-13 (115).  These 
cytokines are best known for promoting the humoral arm of the immune response by enhancing 
the ability of B lymphocytes to produce antibodies and suppression of the development of Th1-
type immune responses.  A Th3 cytokine profile is characterized by the production of IL-10 and 
TGF-ß.  A Th3-biased immune response may also be called a T-regulatory (Treg) response due 
to the ability of IL-10 and TGF-ß to suppress the activity of Th1- and Th2-type biased CD4+ T 
lymphocytes (119).  Although not generally known for their ability to induce cell death of their 
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target cells, CD4+ Th cells can express FasL, affording effector CD4+ T cells the capacity to kill 
tumor cells through an apoptotic pathway (120).  In contrast, the ability to mediate the 
perforin/granzyme pathway of target cell death appears biased towards effector CD8+ CTLs. 
 
1.16. Dendritic Cells 
Dendritic cells (DC), B cells, and macrophages comprise a group of cells termed 
“professional” antigen presenting cells (APC).  Professional APCs play a critical role in the 
presentation of antigens and activation of T cells. Of these 3, DC are recognized as the only APC 
that is reproducibly able to activate naïve T cells (121), and they are the most potent activators of 
antigen-specific memory T cells (122).  This is in part due to their constitutive or inducible 
expression of T cell co-stimulatory molecules (e.g. CD80, CD86, CD40), HLA Class I and II 
molecules, and their production of cytokines, such as interleukin-12, 15, and 18 (122). IL-12 is a 
key cytokine secreted by DC given its ability to polarize the immune response towards a Th1 
phenotype (123) and induce the production of γ-IFN by T lymphocytes (124).  In the periphery, 
DC express the chemokine receptor CCR6 (125) and exist in an immature state which is 
characterized by their ability to capture antigens through a variety of mechanisms.  Such 
mechanisms include macropinocytosis (126), receptor-mediated endocytosis (127), and 
phagocytosis (128).  Immature DC also express low surface levels of HLA molecules, CD80, 
CD86, and CD40.  Upon antigen capture, DC begin to mature, and they lose their ability to 
capture antigens and acquire the ability to stimulate T lymphocytes.  DC maturation is 
characterized by their upregulation of HLA molecules, increased expression of T lymphocytes 
co-stimulator molecules (e.g. CD86, CD80, CD40) and the expression of CD83 (122).  Upon 
maturation DC acquire the ability to migrate towards the secondary lymphoid organs (e.g. 
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spleen, lymph nodes) due to the downregulation of CCR6 and the upregulation of CCR7 (129).  
The expression of CCR7 sensitizes DC to the effects of SLC which is expressed in the secondary 
lymphoid tissues (130).  When they arrive at the secondary lymphoid organs, DC encounter 
CD4+ T cells and induce their activation.  This activation is dependent on the interaction of 
CD40 on the DC and CD40L on the T-helper cell (131).  This contact enables the DC to become 
a more potent activator of CD8+ T cells and induce their differentiation into effector CTLs (122).  
This interaction is crucial for the induction of anti-tumor immunity that is sought for 
immunotherapy protocols in the treatment of cancer.  Although much focus has been placed on 
the role of CTL regarding the fight against cancer, the role of T-helper cells should not be 
forgotten.  Th1-type T-helper cells can produce pro-inflammatory cytokines that can promote 
and recruit anti-tumor immunity into tumor sites (78), whereas Th2-type responses have 
generally not proven to be beneficial for eliciting CTL anti-tumor activity and promoting anti-
tumor immunity in situ. 
 
1.17. T lymphocytes and Cancer Immunotherapy 
With the identification and characterization of tumor antigens expressed by various types of 
cancer, researchers quickly set out to define which derivative peptide epitopes could be 
recognized by anti-tumor T lymphocytes.  The underlying question was that if T cell epitopes 
could be defined, would they prove capable of generating tumor antigen-specific T lymphocytes 
that could also recognize cancer cells and possibly mediate rejection when employed in clinical 
vaccines?  One of the popular methods to generate T cell responses against tumor antigens is the 
use of dendritic cells (DC) and other antigen presenting cells (APC) (132).  Through the 
utilization of DC, tumor antigens pulsed DC have been used to generate anti-tumor immune 
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responses against a diverse array of tumor antigens.  There are several popular methods to 
determine whether or not a tumor antigen derived epitope can be recognized by T lymphocytes.  
These methods include, but are not limited to, RNA transfection (133), DNA transfection (134), 
and viral infection (135).  The most popular method is the use predictive peptide binding 
algorithms that have been developed to determine which peptide sequences from cloned tumor 
antigens would be able to bind to certain HLA allelic molecules (99).  The entire sequence of a 
tumor antigen is analyzed, and peptides with a predicted high affinity for binding to specified 
HLA molecules are synthesized.  From there, peptides can be pulsed onto DC, with the antigen-
loaded DC then co-incubated with autologous T responder lymphocytes in a process called in-
vitro stimulation (IVS.  After 7-10 days of in vitro priming/boosting, responder T lymphocytes 
are then analyzed for their ability to recognize the specific antigens they were stimulated with.  
These T cells can also be co-incubated with tumor cells that express the antigen and HLA allele 
of interest and tested for their ability to recognize tumors that naturally process and present the 
candidate epitope.  These experiments can assess whether T lymphocytes can recognize 
naturally-occurring MHC/peptide complexes presented on tumor cells and whether or not those 
antigens may be relevant for tumor immunotherapy.  Significant numbers of ongoing studies are 
being performed to determine how, when and where to administer tumor antigen-based vaccines 
to afford the greatest degree of clinical efficacy, or whether ex vivo primed anti-tumor T cells 
should be adoptive transferred to yield a high rate of prevention or cures in these patients. 
 
1.18. Monoclonal Antibodies 
One set of tools studied for application as cancer immunotherapeutic agents are monoclonal 
antibodies (mAb).  mAb are proteins that are created by the fusion of a plasma cell with a tumor 
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cell and allow for the continued production of a clonal antibody.  mAb specific for a given tumor 
antigen may bind to that antigen expressed by tumor cells in situ, thereby promoting a cytolytic 
anti-tumor immune response via the recruitment of complement and/or Fc receptor+ natural 
killer (NK) cells (136).  Anti-tumor mAbs may also be therapeutic in the cancer setting if they 
are able to mediate the functional neutralization (e.g. blocking binding sites or functional 
signaling) of tumor antigens (such as RTKs).  For example, the mAb Herceptin binds to the 
Her2/neu tumor antigen, which is a member of the EGFR family of growth factor receptors. This 
binding induces the internalization of Her2/neu, thereby inhibiting the proliferation of Her2/neu 
positive tumors (137). 
mAbs are unique tools for use as cancer immunotherapy agents due to the fact that a 
patients HLA type is not a key factor for accrual into protocols administrating the mAb (i.e. 
passive transfer as a therapy).  All that is necessary is that a tumor must express the tumor 
antigen the mAb is specific for.  This increases the fraction of cancer patients that can be treated 
with this single modality of immunotherapy and opens the door for combinational therapies that 
may combine antibodies and vaccines or adoptive strategies focused on anti-tumor T cells. 
 
1.19. Summary 
With increasing evidence demonstrating that the receptor tyrosine kinase EphA2 is 
overexpressed in a number of epithelial based cancers, with even higher expression in metastatic 
disease, I wanted to investigate whether the EphA2 protein contained peptide epitopes 
recognized by T lymphocytes, in hopes of defining an appropriate treatment modality for patients 
with EphA2+ tumor types, such as melanoma and a diverse array of carcinomas. I used EphA2 
peptide-pulsed DC as in vitro stimulators to ascertain to whether EphA2 peptides could elicit 
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specific T cell responses and an agonist monoclonal antibody (specific for EphA2 that has been 
generated that is able to bind overexpressed EphA2 proteins on the tumor cell surface and not 
bind EphA2 on normal tissues) to induce the internalization and degradation of EphA2 to 
conditionally facilitate the presentation of EphA2-derived CD8+ T cell epitopes. This latter 
treatment as well as our strategies to prevent the activity of LMW-PTP result in an acute increase 
in EphA2 epitopes presented in MHC class I complexes and in the enhanced ability of EphA2-
specific CD8+ T lymphocytes to recognize EphA2+ tumors.  We believe that this may define a 
novel combinational immunotherapy design involving DC vaccination with a consequent 
delivery of agonist anti-EphA2 mAb or PTP inhibitors to promote the CTL-mediated 
(conditional) eradication of EphA2+ tumor lesions in patients.  These studies are significant 
because they have determined the immunogenecity of a new tumor antigen that is overexpressed 
by multiple cancer types and serve as the basis for the development of novel prospective 
immunotherapy protocols designed to elicit, sustain and enhance the in vivo efficacy of EphA2-
specific T cells.  
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Scope of This Thesis 
 We have characterized EphA2 as a tumor-associated antigen in the setting of renal cell 
carcinomas (RCC).  We have observed that a higher expression of EphA2 in primary RCC 
specimens was associated with a shorter (<1yr) time to recurrence of disease, where a low 
expression of EphA2 was associated with a more prolonged disease-free interval.  We have also 
noted that metastatic cell lines express higher levels of EphA2 than do primary RCC cell lines, 
which is consistent with reports of EphA2 playing a role in metastasis in other forms of cancer.  
We then identified immunogenic EphA2-derived peptide epitopes and characterized the 
magnitude and functional nature of CD4+ and CD8+ T cell immune responses against EphA2 in 
HLA-A2+ and/or HLA-DR4+ normal donors and RCC patients.  While both normal donors and 
RCC patients were able to recognize EphA2 epitopes, the functional anti-EphA2 CD4+ T cell 
responses in patients with RCC was disease status-dependent, with patients with either active 
disease or a higher staging of RCC displayed a Type-2 (i.e. IL-5) -biased functional phenotype.  
Patients with NED or early Stage I or II disease primarily displayed a Type-1-biased (i.e. IFN-γ) 
functional phenotype.  Interestingly, we observed that treatment of EphA2+ RCC lines with 
EphA2 agonists restored proper phosphorylation of EphA2 protein and its consequent 
degradation via a proteasome-dependent pathway.  Importantly, this conditional manipulation 
resulted in increased recognition of EphA2+ tumors by EphA2 specific CD8+ T cell clone, 
consistent with the enhanced loading of EphA2 epitopes into tumor cell expressed MHC class I 
complexes.  Finally, given the constitutive underphosphorylation of EphA2 on EphA2+ tumors, 
we were also able to promote EphA2 phosphorylation and proteasomal processing by treating 
tumor cells with PTP inhibitors.  Hence we have characterized EphA2 as a carcinoma-associated 
antigen and determined pharmacologic means by which to enhance tumor cell recognition by 
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anti-EphA2 T cells.  We believe that combinational vaccine + conditional tumor processing 
strategies should be explored as novel immunotherapeutic strategies for patients with EphA2+ 
tumors. 
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Preface Chapter 2 
 Using an immunohistochemistry approach and archived patient tissues, our goal was to 
determine whether the level of EphA2 protein overexpression in resected primary RCC tumor 
specimens was predictive of the time to disease recurrence (TTR) in patients rendered free of 
disease post-surgery.  We analyzed 3 groups of patients; i.e. those who recurred in: (1)< 1yr, (2) 
between 1 and 5 years and (3) more than 5 years post-surgery.  We discovered that high relative 
expression of EphA2 in primary tumor lesions was associated with a shorter TTR (<1yr), higher 
tumor volume, and higher Factor VIII+ blood vessels indicative of tumor neoangiogenesis.  We 
also found that primary tumors with high expression levels of EphA2 were less structurally 
organized and displayed dysregulated intracellular EphA2 expression patterns when compared to 
primary tumors expressing lower levels of EphA2 protein.   
 The studies in Chapter 2 support the relevancy of EphA2 as a novel tumor antigen that is 
linked with tumor lesions that may be better positioned to progress and metastasize.   
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2.1. ABSTRACT 
While normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent 
studies have shown that the receptor tyrosine kinase (RTK) EphA2 is overexpressed in numerous 
epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic 
lesions.  Using specific anti-EphA2 mAb 208 and immunohistochemistry, we evaluated EphA2 
protein expression levels in renal cell carcinoma (RCC) specimens surgically resected from 
patients resulting in clinical cures.  RCC lesions expressing higher levels of EphA2 tended to be 
larger, more-highly-vascularized tumors.  Perhaps most notable, the degree of EphA2 
overexpression (vs. normal matched autologous kidney tissue) appeared predictive of short (< 1 
Yr) vs. longer (> 1 Yr)-term disease-free interval among the RCC patients evaluated.  These data 
suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical 
management of patients who have been successfully treated with surgery, but who may be at a 
greater risk for accelerated disease recurrence. 
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 2.2. INTRODUCTION 
 
The Eph family of molecules constitutes the largest known family of receptor tyrosine 
kinases (RTKs), consisting of two classes of receptors, EphA and EphB, and two classes of 
corresponding ligands, ephrin-A and ephrin-B, respectively.  Ephrin-A ligands are attached to 
the cell surface via GPI-anchors and preferentially bind only EphA receptors.  Ephrin-B ligands 
are transmembrane proteins and primarily bind EphB receptors.  Largely known for their role(s) 
in neuronal development and tissue remodeling (138, 139), recent reports suggest that Eph 
receptors also play a role(s) in oncogenesis (36, 56-58, 60, 140-143). 
 EphA2 is of particular interest due to evidence suggesting its involvement in developing 
malignancies.  EphA2 is a 130kDa protein normally localized to sites of cell-to-cell contact, 
where it plays a role in contact growth inhibition (36).  However cellular overexpression of 
EphA2, either as a result of its constitutive dysregulation or ectopic gene insertion, results in the 
disruption of cell-to-cell contacts, and enhancement of cell-to-extracellular matrix (ECM) 
attachments (36).  As a result, tumor cells that overexpress EphA2 exhibit increased motility and 
invasive properties, consistent with a pro-metastatic phenotype (36).  Overexpression of EphA2 
has been observed in numerous cancer types (140), including melanoma (141, 142) and 
carcinomas of the breast (57, 58, 143), lung (144), pancreas (60) and prostate (56). 
 It has been recently suggested that the quantitative levels of EphA2 expressed by cancer 
cells might provide useful prognostic information with regard to the metastatic potential of 
human tumors in situ and the clinical disease course of patients with cancer.  Kinch et. al. (145, 
146) reported that high level EphA2 expression in primary lung tumors is predictive of brain 
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metastases, where lower levels predict either extended disease-free status or locoregional 
(contralateral) lung metastasis.  Likewise, Miyazaki et. al. (147) reported a significant correlation 
between EphA2 overexpression in esophageal squamous cell carcinoma with the presence of 
lymph node metastasis, the number of lymph node metastasis, and less well differentiated 
tumors.  Five-year survival rates were also reported to be lower for patients with EphA2+ tumors 
vs. those patients with EphA2-negative tumors (147).  In light of this evidence, and our previous 
report supporting the prevalent overexpression of EphA2 in RCC (148), we performed 
immunohistochemical analyses to determine whether the relative level of EphA2 expressed by 
resected RCC tumors was indicative of the disease-free interval observed for a given surgically-
cured patient. 
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 2.3. MATERIALS AND METHODS 
 
2.3.1. Patients and Tissues 
RCC tumor and adjacent normal kidney specimens were collected from a total of 34 
patients with consent under IRB-approved protocols. All patients were treated by radical or 
partial nephrectomy and rendered disease-free.  Patient and tumor characteristics and time-to-
recurrence are indicated in Table 2.  Among these patients, a subset of 8 individuals, remain 
clinically-free of disease for more than 13 years post-surgery.  For these patients, the time since 
surgery is reported as their “disease-free interval”.  All the resected tissues were fixed in 
paraformaldehyde (Sigma Chemical Co., St. Louis, MO) and embedded in paraffin.   
 
2.3.2. Construction of RCC Tissue Microarray (TMA) 
Twelve RCC that recurred within 1 year or surgery, 16 RCC that recurred within 1-10 years 
after surgery and 13 RCC that remained disease-free 10 years after surgery were selected for 
construction of the RCC TMA.  All cases were retrieved from the surgical pathology file at the 
Department of Anatomic Pathology of the Cleveland Clinic Foundation, and were reviewed and 
the diagnoses confirmed.  One representative paraffin block from each case was used to 
construct a tissue microarray.  Briefly, areas of interest (tumor or normal adjacent tissue) were 
traced with a marker pen on an H&E stained slide.  The corresponding areas were then marked 
on the corresponding paraffin blocks.  The TMA was made on a manual TMA arrayer (Beecher 
Instruments, Sun Prairie, WI). Three 1.5 mm-thick tissue cores were taken from each block to 
build the TMA.  After construction, 4-micron sections were cut, mounted on Superfrost Plus 
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glass slides and stored for future use.  An H&E staining was performed on the initial slide to 
verify the histologic diagnosis, with a map of case number and tissue diagnosis maintained in a 
Microsoft Excel spreadsheet. 
 
2.3.3. Immunohistochemistry 
Tissue microarray slides were de-paraffinized and stained with a murine anti-hEphA2 mAb 
208 (1:100 dilution; MedImmune, Inc., Gaithersburg, MD), rabbit anti-human Factor VIII mAb 
(1:400 dilution; Dako Corp., Carpinteria, CA), or normal mouse/rabbit IgG control Ab (1:200 
dilution; Sigma) in immunohistochemical analyses.  Detection was determined by using 
Vectastain anti-IgG and NovaRed kits (Vector Labs, Burlingame, CA). Three independent 
evaluators analyzed slides under 40x magnification and scored EphA2 expression using an 
arbitrary scale of 0 (low) – 5 (high).  Three serial sections from each specimen were evaluated in 
order to reduce intra- and inter-specimen scoring variations.  The mean (+/- S.D.) value of the 
nine aggregate determinations (3 readers x 3 sections/lesion) of EphA2 expression intensity for 
each tumor and matched normal adjacent kidney specimen were calculated for each patient.  
EphA2 staining results are reported as a ratio of EphA2 expression in tumor sections vs. matched 
normal adjacent kidney.   
2.3.4. Statistical Analyses 
 Statistical differences between groups were evaluated using a two-tailed Student’s T test, 
with p values < 0.05 considered significant.  
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 2.4. RESULTS 
 
2.4.1. RCC lesions express variable levels of EphA2. 
Curative surgery was performed on 34 RCC patients (Table 2).  The resected tissues were 
dissected into tumor and uninvolved “normal” kidney specimens, prior to being formalin-fixed, 
assembled into tissue arrays, and sectioned as described in Materials and Methods.  Each tissue 
array contained 3 “cores” derived from a given patient’s tumor and normal adjacent kidney 
specimen, such that each slide analyzed contained 3 replicate sections of each tumor/normal 
kidney tissue resected.  After de-paraffinization, slides were subjected to immunohistochemical 
analyses for EphA2 expression using the specific anti-EphA2 mAb208 vs. normal IgG control 
Abs.  
 RCC tumor specimens exhibited profound variability in their level of EphA2 expression.  
For example, patient #19’s tumor overexpressed EphA2 relative to their normal adjacent kidney 
tissue, and the pattern of expression appeared dysregulated, with EphA2 protein located 
throughout the cytoplasm and on the tumor cell membrane (Fig. 3A).  This was vastly different 
from the pattern of distribution in adjacent normal renal tissue (Fig. 3C), where EphA2 
expression was restricted to the epithelial cells lining the tubules within the kidney.  In marked 
contrast, RCC tumor resected from patient #16 exhibited a weaker EphA2 staining pattern (Fig 
3e), with the intensity of EphA2 expression by the tumor indistinguishable from that of the 
normal, matched kidney tissue (Fig. 3G). 
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 2.4.2. Larger, more vascularized tumors tend to exhibit higher levels of EphA2 
expression. 
Recent reports in breast carcinoma and melanoma models suggest that EphA2 expression in 
situ may be associated with larger, better vascularized tumors (74, 149).  Furthermore, EphA2 
blockade limits murine breast tumor growth in vivo (77), suggesting that EphA2 plays a role in 
tumor progression.  We therefore analyzed whether the relative EphA2 expression levels 
observed in RCC lesions was correlated with resected tumor volume and the degree of tumor 
vascularity.  For these studies, the relative expression level of EphA2 was determined in tumor 
vs. normal adjacent kidney tissue in a blinded manner by 3 individuals utilizing a 0-5 scoring 
scale, with 5 representing strongest expression and 0 representing lack of expression by the 
stained tissue.  This value was then plotted versus the volume of the resected tumor (from Table 
2).  As shown in Figure 4A, we observed a trend between increased RCC tumor expression of 
EphA2 and tumor volume, although this correlation only provided an R2 value of 0.33 and would 
not be considered statistically significant (p=.093).  Similarly, an immunohistochemical analysis 
of blood vessels in RCC lesions using anti-Factor VIIII antibodies (Figure 4B) revealed that a 
trend between the degree of EphA2 expression and the number of blood vessels per tumor 
section (R2 = 0.32, p=.005). 
 
2.4.3. High levels of EphA2 Expression by EphA2+ Tumors Appear Predictive of Acute 
Relapse 
Given previous reports supporting a prognostic potential for EphA2 expression in lung and 
esophageal cancer (145, 146), we next evaluated whether the relative level of EphA2 expressed 
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by resected RCC tumors was predictive of the disease-free interval of a given patient cured by 
therapeutic surgery.  For these studies, patient materials were divided into 3 cohorts for 
prospective analyses; a) patients who recurred within 1 year of surgery (n = 10), b) patients who 
recurred between 1 and 5 years of surgery (n = 13), and c) patients who recurred or who remain 
disease-free 5 or more years post-surgery (n = 11).  
When data from all 34 patients was evaluated (Figure 5), we observed that the disease-
free interval for a given patient was inversely related to the relative intensity of EphA2 expressed 
by the patient’s resected RCC tumor (vs. the matched normal kidney tissue).  This correlation 
was most striking (p = 0.0003) when considering patients who recurred in less than 1 year from 
the time of their curative surgery (relative EphA2 expression = 3.81 (mean) + 0.77 (S.D.)) vs. 
patients who remain disease free now more than 5 years post-treatment (relative EphA2 
expression = 1.27 + 0.37).  A p value < 0.001 was still obtained when considering patients who 
recurred within their first year of surgery vs. those patients who relapsed between 1-5 years post-
surgery (relative EphA2 expression = 1.60 + 0.57).  However, a comparison of relative tumor 
cell expression of EphA2 amongst patients recurring between 1-5 vs. > 5 years post-surgical cure 
did not support any statistically-significant difference (i.e. p = 0.43).  This suggests that the 
relative level of EphA2 expressed by RCC tumors resected from patients that are rendered 
disease-free after surgery provides an index that may be predictive of how quickly a treated 
patient will recur. 
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 2.5. DISCUSSION 
The key discovery of this study is that the expression of EphA2 in resected RCC tumors 
may serve as a prognostic indicator of disease-free interval in patients that are cured by 
therapeutic surgery.  RCC lesions exhibiting the highest expression levels of EphA2 protein 
displayed the most abbreviated time to disease recurrence (i.e. < 1 year), while patients whose 
tumors expressed levels of EphA2 that were indistinguishable from normal adjacent kidney 
tissue remained disease-free for extended periods of time post-surgery.  When combined with 
recent studies in lung (146) and renal (148) carcinoma, these results support EphA2 expression 
as an important index related to disease progression, metastatic spread and durability of 
therapeutic efficacy in multiple tumor histologies. As EphA2 can be overexpressed by a broad 
range of cancer types (56-58, 60, 140-144), the prognostic utility of this marker may prove 
important in the monitoring and clinical management of a large cohort of cancer patients. 
 Our finding that EphA2 expression tended to be directly associated with tumor volume 
(i.e. tumor burden) and the number of tumor-associated Factor VIII+ vessels may relate to the 
involvement of EphA2 and its primary ligand Ephrin-A1 in the formation of neovessels in 
progressor tumor lesions (74).  When the EphA2 signaling pathway is blocked, VEGF-mediated 
angiogenesis is inhibited (149).  Furthermore, recent studies have also shown that the expression 
of EphA2 is associated with increased tumor cell proliferation and increased tumor thickness in 
the melanoma setting (150).  Overall, these data suggest that overexpression of EphA2 by tumor 
or endothelial cells within the tumor microenvironment provide a growth advantage to the 
neoplastic cells, favoring a progressor lesion in situ. 
 36
 The reason(s) why the EphA2 protein becomes overexpressed in aggressive cancers 
remains incompletely understood, but likely involves both transcriptional and post-
transcriptional mechanisms.  cDNA array analyses provide strong support for elevation of 
EphA2 mRNA in the setting of melanoma (140, 149), and a similar finding would be anticipated 
for at least a subset of renal cell carcinomas.  Alternatively, or additionally, it has been recently 
suggested that the steady-state level of “accumulated” EphA2 in cancer cells may be regulated 
by: 1) defective ligand-induced EphA2 activation and/or 2) the activity of the low molecular 
weight-protein tyrosine phosphatase (LMW-PTP) which prevents the ubiquitination and 
degradation of the phosphorylated EphA2 RTK generated after receptor crosslinking (67, 151).  
Given these findings, clinical approaches invoking specific RNAi, agonist antibodies (151) or 
PTP inhibitors may serve to reduce EphA2 expression within tumor lesions, resulting in less 
aggressive tumor cells, prevention of tumor neoangiogenesis and improved clinical outcomes. 
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 Preface Chapter 3 
 Using DC-based in vitro vaccinations as a model system, our goal was to define EphA2-
derived epitopes recognized by CD8+ and CD4+ T-lymphocytes.  We analyzed T cell responses 
to 5 putative HLA-A2-presented and 3 putative HLA-DR4-presented EphA2 epitopes in both 
normal donor and patients with RCC.  All 5 HLA-A2 binding peptides (EphA2162-70, EphA2391-
99, EphA2546-54, EphA2883-91, and EphA2961-99) and 3 HLA DR4 binding peptides (EphA2 53-68, 
EphA263-75, and EphA2663-78 were recognized by both normal donors and RCC patients.  EphA2-
specific T cells were able to recognize EphA2+ tumors in an HLA-A2 (in the case of SLR24) 
and HLA-DR4 (in the case of PC3.DR4) restricted manner.  The functionality of CD4+ Th cells 
was biased in a manner dependent on the patient’s disease status, with a Th2-bias most notable 
among patients with active, advanced stage disease.  Patients who were disease-free at the time 
of analysis or who had limited locoregional Stage I disease tended to exhibitTh1-biased 
immunity to EphA2 peptide epitopes. 
 The studies in Chapter 3 support the immunogenicity of EphA2 epitopes and that these 
are naturally processed and presented in MHC complexes by EphA2+ tumor cells.  This data was 
reported in Cancer Research in 2003, in which I was a co-first author.  Further studies in 
Chapters 4 and 5 will address whether conditional modulation of EphA2 expression can 
enhance the immune response to EphA2+ tumors. 
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 3.1. ABSTRACT 
We have evaluated CD8+ and CD4+ T cell responses against a new tumor-associated 
antigen, the receptor tyrosine kinase EphA2, which is broadly expressed in diverse cancer 
histologies and is frequently overexpressed in advanced stage/metastatic disease.  We report 
herein that EphA2 is overexpressed in renal cell carcinoma (RCC) cell lines and clinical 
specimens of RCC and find that the highest levels of EphA2 are consistently found in the most 
advanced stages of the disease.  We identified and synthesized five putative HLA class I-binding 
and three class II-binding peptides derived from EphA2 that might serve as targets for immune 
reactivity.  Each peptide induced specific, tumor-reactive CD8+ or CD4+T cell responses as 
measured using IFN-γ ELISPOT assays.  The EphA2 peptides elicited relatively weak responses 
from CD8+ T cells derived from normal healthy volunteers or from RCC patients with active 
disease. In marked contrast, immune reactivity to EphA2-derived epitopes was greatly enhanced 
in CD8+ T cells that had been isolated from patients who were rendered disease-free, after 
surgery.  Furthermore, ELISPOT analyses demonstrated prominent EphA2-restricted Th1-type 
CD4+ T cell activity in patients with early-stage disease, whereas Th2-type and Tr-type 
responses predominated in patients with more advanced forms of renal cell carcinoma.  These 
data suggest that the immune system of cancer patients actively monitors EphA2-derived 
epitopes and that the magnitude and character of T cell responses to EphA2 epitopes may convey 
much-needed predictive information about disease stage and outcome. 
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 3.2. INTRODUCTION 
The molecular identification of tumor antigens recognized by the immune system has 
paved the way for the development of new immunotherapeutic strategies for the treatment of 
cancer (152-162). While many cytotoxic T lymphocyte (CTL)-defined tumor-associated epitopes 
have been applied clinically in cancer vaccinations (163-167), comparatively few class II-
restricted epitopes recognized by CD4+ T cells have been identified and clinically integrated to 
date (98, 168-175). Current paradigms suggest that CD4+ T cells (at least Th1-type) play critical 
roles in the optimal induction and maintenance of clinically beneficial tumor immunity (168, 
176).  Hence, CD4+ and CD8+ T cell epitopes derived from antigens that are unique to, or 
overexpressed on, tumor cells may provide effective vaccine components. 
The Eph family of molecules constitutes the largest family of receptor tyrosine kinases in 
the human genome. Eph kinases are comprised of two major classes (EphA and EphB), which 
are distinguished by their specificities for ligand (ephrin-A and ephrin-B, respectively, (1)). 
Largely known for their role in neuronal development (16, 139, 177), recent reports suggest that 
Eph receptors play a role in carcinogenesis (35, 178-180).  For example, EphA2 is overexpressed 
and functionally altered in a large number of different cancers, where it appears to promote the 
development of disseminated disease. In normal cells, EphA2 localizes to sites of cell-to-cell 
contact (35), where it may play a role as a negative regulator of cell growth. In contrast, EphA2 
is frequently overexpressed and often functionally dysregulated in advanced cancers, where it 
contributes to many different aspects of malignant character.  Overexpression of EphA2 has been 
observed in a wide array of solid tumors, including melanoma (141, 142) and prostate (56), 
breast (61) and lung (144) carcinomas.  Indeed, the highest degree of EphA2 expression among 
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tumors is most commonly observed in metastatic lesions (56, 179).  Given this pattern of 
expression in tumor cells, immunologic targeting of EphA2 in situ could prove effective at 
eliminating disseminated disease.  Furthermore, with relevance to diagnosis and immune 
monitoring of patients, the frequency and functional status of T cells reactive against EphA2 may 
serve as an appropriate index of “clinically important” anti-tumor immunity in patients with 
diverse forms of cancer.  
In the clinical setting, several findings suggest that T cell-mediated immunity provides a 
safeguard against the development and progression of RCC and may effectively mediate the 
regression of established lesions.  RCC lesions are typically infiltrated with large numbers of 
lymphocytes (181, 182), though the benefits of leukocytic infiltration upon clinical outcome 
remain unknown (183).  While this may reflect variance in the functional subsets of CD4+ and 
CD8+ T cells in these infiltrates, data addressing the prognostic benefit of Th1/Tc1- vs. Th2/Tc2-
biased immunity in RCC patients has been equivocal (184, 185).  A better understanding of the 
constitutive nature and specificity of CD8+ and CD4+ T cell responses in RCC patients will 
likely provide insights necessary to design, implement, and monitor more effective treatments. 
In the present study, we demonstrate that high levels of EphA2 expression are observed 
in the setting of RCC and that some patients with this disease exhibit both CD8+ and CD4+ T 
cell responses to novel EphA2-derived epitopes.  More importantly, our findings suggest that the 
reactivity of T cells against EphA2 may be useful in distinguishing disease status and outcome. 
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 3.3. MATERIALS AND METHODS 
 
3.3.1. Cell Lines and Media 
The T2.DR4 (HLA-A2+/-DRB1*0401+; (175)) cell line (kindly provided by Dr. Janice 
Blum, Indiana University School of Medicine, Indianapolis, IN) was used as the peptide-
presenting cell in ELISPOT assay.  The following SLR20-SLR26 clear-cell RCC lines were 
evaluated in Western Blot analyses.  The normal, human proximal tubular epithelial kidney cell 
line HK-2 (American Type Tissue Collection, ATCC, Rockville, MD) was also evaluated in 
Western Blot analyses.  Hypothetically, HK-2 represents a normal control cell line, although it 
has been transformed by transfection with the HPV-16 E6/E7 genes (186).  The EphA2+ PC-3 
and PC-3.DR4 prostate carcinoma cell line was included as positive controls for Western Blot 
analysis of EphA2 protein expression (56) and were also used as targets in ELISPOT assays.  All 
cell lines were maintained in RPMI-1640 culture medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 10mM 
L-glutamine (all reagents from GIBCO/Life Technologies, Grand Island, New York) in a 
humidified atmosphere under 5% CO2 tension at 37°C. 
 
3.3.2. Peripheral Blood and Tumor Specimens 
Peripheral blood was obtained by venipuncture from 40 patients diagnosed with RCC and 
14 normal individuals and was collected into heparinized tubes.  Peripheral blood lymphocytes 
(PBLs) were isolated by centrifugation on a Ficoll-Hypaque gradient (LSM, Organon-Teknika, 
Durham, NC).  RCC tumor lesions and matched normal kidney tissue were surgically-resected 
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and paraffin-embedded.  Informed consent, under an IRB-approved protocol, was obtained from 
all patients prior to sample acquisition. Patient and normal donor information is provided in 
Table 3.  All individuals included were HLA-A2+ or/and HLA-DR4+, as determined by 
fluorescence-activated cell sorter analysis using the HLA-A2-specific antibodies (BB7.2 and 
MA2.1) and HLA-DR4-specific antibody (anti-HLA-DR4 monoclonal antibody clone 359-
13F10, IgG, kindly provided by Dr. Janice Blum, Indiana University School of Medicine, 
Indianapolis, IN). Among the RCC patients and normal individuals, 9 patients and 6 normal 
individuals expressed both the HLA-A2 and HLA-DR4 major histocompatibility antigens. 
 
3.3.3. Western Blot Analyses 
Tumor cells (5-10 x 106) were analyzed for EphA2 expression via Western blots using the 
anti-human EphA2 polyclonal antibody (clone: C-20) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA). Cell pellets were lysed using 200µl of 1% NP-40 in PBS containing protease 
inhibitors (Complete, Boehringer Mannheim, Indianapolis, IN) for 1 hour on ice. After 
centrifugation at 13,500 x g for 30 minutes, the supernatant was mixed 1:1 with SDS-PAGE 
running buffer and proteins separated on 10% PAGE gels, prior to electro-blotting onto 
nitrocellulose membranes (Millipore, Bedford, MA).  Blots were imaged on Kodak X-Omat Blue 
XB-1 film (NEN Life Science Products, Boston, MA) using horseradish peroxidase (HRP)-
conjugated goat anti-rabbit Ig (Biorad, Hercules, CA) and the ECL chemilluminescence 
detection kit (NEN Life Science Products). 
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 3.3.4. Immunohistochemistry for EphA2 in RCC tissue 
  
RCC tumor specimens were obtained surgically under an IRB-approved protocol and paraffin-
embedded.  Five-micron sections were de-paraffinized and rehydrated in double-distilled H20 
and then PBS.  Anti-EphA2 mAb (Ab 208; mIgG1) or isotype-matched control mAb was 
incubated on sections for 1h at RT.  After PBS washing, sections were incubated with 
biotinylated goat anti-rabbit IgG (Vector Laboratories) for 20 min at RT, and after washing, were 
then incubated with avidin-biotin-complex peroxidase (Vectastain ABC kits, Vector 
Laboratories).  After a subsequent wash, reaction products were developed using a Nova Red 
substrate kit (Vector Laboratories), and nuclei were counterstained with hematoxylin.  The 
expression of EphA2 was evaluated independently by two investigators with a microscope under 
40X magnification. 
 
3.3.5. Peptides selection and synthesis 
The protein sequence of EphA2 protein was obtained from GENBANK (accession number 
XP 048780) and analyzed for HLA-A0201 and HLA-DRB1*0401 binding peptides using neural 
network algorithms (187, 188).  The top ten candidate HLA-A2 binding peptides were then 
analyzed for their ability to be generated by proteasomal cleavage using the PAProC prediction 
algorithm (www.uni-tuebingen.de/uni/kxi/), with only those peptides capable of being processed 
by the proteasome selected for synthesis.  All peptides were synthesized by Fmoc chemistry by 
the University of Pittsburgh Cancer Institute’s (UPCI) Peptide Synthesis Facility.  Peptides were 
>96% pure based on high-performance liquid chromatography profile and mass spectrometric 
analysis performed by the UPCI Protein Sequencing Facility.   In total, we evaluated reactivity to 
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five HLA-0201 and three HLA-DR0401 predicted binding peptides that received high binding 
scores (Table 4). 
 
3.3.6. Antigen Stimulation of PBLs 
PBLs were resuspended at 107/ml in AIM-V medium (GIBCO/Life Technologies) and were 
incubated for 60 min at 37oC in a humidified 5% CO2 incubator.  Non-adherent (T cell-enriched) 
cells were gently washed out with PBS and subsequently frozen.  The plastic adherent cells were 
cultured in AIM-V medium supplemented with 1000 units/ml rhGM-CSF (Immunex 
Corporation, Seattle, WA) and 1000 units/ml rhIL-4 (Schering-Plough, Kenilworth, NJ).  Seven 
days later, dendritic cells (DCs) were harvested and used to stimulate autologous CD8+ or CD4+ 
T cells.  Non-adherent autologous cells were used as “enriched” sources of T cell responders.  
CD8+ T cells (in HLA-A2-positive patients and healthy donors) or CD4+ T cells (in HLA-DR4-
positive patients and healthy donors) were positively isolated to >98% purity using specific 
magnetic beads (MACS; Miltenyi Biotec, Auburn, CA).  Two hundred thousand DCs were 
cocultured with 2 x 106 CD8+ or CD4+ T cells with 10µg/ml peptide for 1 week.  On day 7 of in 
vitro stimulation, the responder CD8+ T cells or CD4+ T cells were harvested and analyzed in 
ELISPOT assays. 
 
3.3.7. IFN-γ and IL-5 ELISPOT assays for Peptide-Reactive CD8+ T cells and CD4+ T 
Cell Responses 
To evaluate the frequencies of peripheral blood T cells recognizing peptide epitopes, 
ELISPOT assays for IFN-γ and IL-5 were performed as previously described (189).  CD8+ T cell 
responses were evaluated by IFN-γ ELISPOT assays only, while CD4+ T cell responses were 
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evaluated by both IFN-γ (Th1) and IL-5 (Th2) ELISPOT assays.  For ELISPOT assays, 96-well 
multiscreen hemagglutinin antigen plates (Millipore, Bedford, MA) were coated with 10 µg/ml 
of anti-human IFN-γ mAb (1-D1K; Mabtech, Stockholm, Sweden) or 5 µg/ml of anti-human IL-
5 (Pharmingen-BD, San Diego, CA) in PBS (GIBCO/Life Technologies) overnight at 4oC. 
Unbound antibody was removed by four successive washing with PBS. After blocking the plates 
with RPMI-1640/10% human serum (1hr at 37oC), 105 CD8+ T cells or CD4+ T cells and 
T2.DR4 cells (2 x 104 cells) pulsed with 10 µg/ml synthetic peptides were seeded in triplicate in 
multi-screen hemagglutinin antigen plates. Control wells contained CD8+ or CD4+ T cells with 
T2.DR4 cells pulsed with HIV-nef190-198 peptide (AFHHVAREL) or Malaria-CS326-345 peptide 
(EYLNKIQNSLSTEWSPCSVT), or T2.DR4 cells alone. Culture medium (AIM-V; GIBCO/Life 
Technologies) was added to yield a final volume of 200µl/well.  To validate the HLA-A2 or -
DR4-restricted nature of T cell reactivity, 5 µg of blocking anti-HLA-A2 (BB7.2) or anti-HLA-
DR4 (359-13F10) were added to some ELISPOT wells.  The plates were incubated at 37oC in 
5% CO2 for 24 hr for IFN-γ assessments, and 40 hr for IL-5 assessments.  After incubation, the 
supernatants of the culture wells were harvested for analyses by ELISA.  Cells were removed 
from the ELISPOT wells by washing with PBS/0.05% Tween 20 (PBS/T). Captured cytokines 
were detected at sites of their secretion by incubation for 2 hr with biotinylated mAb anti-human 
IFN-γ (7-B6-1; Mabtec) at 2 µg/ml in PBS/0.5%BSA or biotinylated mAb anti-human IL-5 
(Pharmingen) at 2 µg/ml in PBS/0.5%BSA.  Plates were washed six times using PBS/T, and 
avidin-peroxidase complex (diluted 1:100; Vectastain Elite Kit; Vector Laboratories, 
Burlingame, CA) was added for 1 hr.  Unbound complex was removed by three successive 
washes using PBS/T, then with three rinses with PBS alone. AEC substrate (3-Amino-9-
ethylcarbazol; Sigma, St. Louis, MO) was added and incubated for 5 min for the IFN-γ 
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ELISPOT assay and the TMB substrate for peroxidase (3,3’,5,5’-Tetramethylbenzidine; Vector 
Laboratories) was added and incubated for 10 min for the IL-5 ELISPOT assay. Spots were 
imaged using the Zeiss AutoImager (and statistical comparisons made using a two-tailed 
Student’s T-test).  The data are represented as mean IFN-γ or IL-5 spots per 100,000 T cells 
analyzed. 
 
3.3.8. ELISAs 
The supernatants harvested from CD4+ T cell ELISPOT plates were also analyzed for 
TGF-β and IL-10 content by ELISAs. Supernatants were isolated from ELISPOT plates at the 
endpoint of the culture period and frozen at –20°C until analyses in specific cytokine ELISAs. 
Cytokine capture and detection antibodies and recombinant cytokines were purchased from BD-
Pharmingen (San Diego, CA) and used in ELISA assays per the manufacturer’s instructions. The 
limit of detection for the TGF-β and IL-10 assays were 60 pg/ml and 7 pg/ml, respectively. 
 
3.3.9. Statistical Analyses 
  Statistical significance of differences between the two groups was determined by applying 
Student’s t test or two sample t test with Welch correction after each group had been tested for 
equal variance. We defined statistical significance as a p value of less than 0.05. 
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3.4. RESULTS 
 
3.4.1. Expression of EphA2 in tumor cell lines and in RCC tissues 
 EphA2 was overexpressed in malignant renal epithelial cell and Western blot analyses 
were used to verify EphA2 protein levels in RCC cell lines (Figure 6A).  Metastatic RCC lines 
expressed EphA2 at greater levels than primary RCC lines; and were similar to the levels of 
staining previously noted for the prostate carcinoma PC-3 (56).  While used as a model for 
normal proximal kidney endothelial cells, the HK-2 cell line is HPV-16 E6/E7-transformed and 
expresses levels of EphA2 consistent with those observed for primary RCC lines.  Normal PBLs 
expressed undetectable levels of EphA2 protein.  Consistent with these findings, 
immunohistochemical analyses performed on paraffin-embedded RCC specimens (Figure 6B, 
Table 3) verified intense expression of EphA2 in 13 of 14 evaluable patient tumor biopsies. 
 
3.4.2. Identification of EphA2 epitopes recognized by T cells 
To identify potential T cell epitopes, the EphA2 protein sequence was subjected to 
algorithms designed to identify putative HLA-A2 binding motifs and sites of proteasomal 
cleavage. Similarly, a neural network algorithm was used to identify EphA2 peptide sequences 
that would be predicted to bind HLA-DR4 and have the potential to serve as CD4+ T cell-
recognized epitopes (187).  In aggregate, 8 peptides were synthesized for subsequent analyses; 
and among these, 5 peptides were predicted to serve as CD8+ T cell epitopes and 3 peptides were 
predicted to serve as Th epitopes (Table 4). 
Peripheral blood T cells were isolated from normal HLA-A2+ and/or -DR4+ donors and 
stimulated with autologous DCs that had be previously loaded with relevant synthetic peptides.  
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Responder T cells were subsequently evaluated for specific reactivity against peptide-pulsed 
T2.DR4 (HLA-A2+/DR4+) antigen-presenting cells and renal cell carcinoma cell lines that 
expressed the EphA2 antigen and HLA-A2 and/or HLA-DR4.  The IFN-γ ELISPOT assay was 
used to evaluate 8 HLA-A2+ donor CD8+ T cell responses to the 5 putative CTL epitopes as 
well as 7 HLA-DR4+ donor CD4+ T cell reactivities against the 3 potential Th epitopes. 
Each peptide was recognized by at least one normal donor, and only one donor (HLA-DR4+) 
failed to respond to any of the EphA2 (Th) epitopes (Table 5).  Among the HLA-A2 donors, the 
EphA2546-554 and EphA2883-891 peptides were most commonly reacted against (6/8 donors 
evaluated), with the responses to EphA2883-891 typically being of a higher frequency.  Among the 
HLA-DR4+ donors evaluated, 6/7 donors responded against at least one predicted EphA2-
derived Th epitope, with responses against the EphA63-75 and EphA2663-677 being most prevalent.  
Bulk and cloned peptide-reactive T cell lines derived from HLA-A2+ or -DR4+ donors 
recognized EphA2+ tumor cell lines in the appropriate HLA class I- or class II- (HLA-A2 or -
DR4) restricted manner (Figure 7) 
 
3.4.3. Analysis of peptide-specific IFN-γ release by peripheral blood CD8+ T cells in 
ELISPOT assays 
We next assessed peripheral blood CD8+ T cells responses against these sequences in 29 
HLA-A2+ RCC patients (Table 3) and 10 HLA-A2+ normal donors.  CD8+ T cells were 
enriched to 98% purity for all experiments. Responses were evaluated using IFN-γ ELISPOT 
assays after 7 day “primary” in vitro stimulations. As shown in Figure 8 , the number of IFN-γ 
spots (per 100,000 CD8+ T cells) observed for T cell responses against EphA2 peptides in HLA-
A2+ patients prior to surgery (Pre-Op) or patients with residual disease after surgery (Post-RD) 
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were as low as those observed in normal HLA-A2+ donors. In contrast, elevated ELISPOT 
reactivity to EphA2 epitopes was observed in RCC patients who were categorized as disease-free 
(no-evidence of disease: NED) after surgery (Post-NED).  Interestingly, CD8+ T cells from RCC 
patients exhibiting long-term survival (Post-LTS; > 2 year survival post-surgery) despite having 
some degree of active disease also showed elevated ELISPOT reactivity to EphA2 CTL epitopes.  
There were no significant differences in anti-EphA2 CD8+ T cell responses when comparing 
patients with Stage I vs. Stage IV, if the patient had active disease (Figure 9).  Only patients that 
were analyzed at a time when they were disease-free (i.e. no evidence of disease, NED) or if they 
were long-term survivors, exhibited CD8+ T cells with elevated reactivity to EphA2 epitopes 
(Figure 9). 
We evaluated the change of CD8+ T cell reactivity against EphA2 peptides pre- and post-therapy 
in 4 HLA-A2+ patients (Figure 10).  Three of these individuals were Stage I patients who had 
local disease prior to surgical intervention, while the remaining patient had Stage IV disease.  
Notably, CD8+ T cell reactivity against EphA2 peptides was very low prior to surgery in all four 
RCC patients.  After being rendered free of disease, CD8+ T cell reactivity against EphA2-
derived CTL epitopes was significantly increased in each of the three Stage I patients.  In marked 
contrast, the single evaluable Stage IV RCC patient, who had residual tumor burden after 
surgery, remained poorly responsive to EphA2 peptides (Figure 10). 
 
3.4.4. Peptide-specific IFN-γ and IL-5 release by CD4+ T cells in ELISPOT assay 
 
IFN-γ (Th1-type) and IL-5 (Th2-type) ELISPOT assays were used to discern the altered 
frequency and functional bias of patient-derived Th cells against EphA2 peptides. Peripheral 
blood T cells were stimulated for one week with peptide-pulsed immature autologous DC (which 
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do not appear to skew the Th1/Th2 balance, (189) prior to CD4+ T cell isolation and ELISPOT 
analyses.  The frequencies of CD4+ T cell responders against EphA2 peptides were evaluated in 
19 HLA-DR4+ RCC patients (Table 3). 
The functional nature of T cell reactivity towards EphA2 related to disease progression. 
Patients with Stage I disease patients displayed strongly Th1-polarized reactivity against EphA2 
peptides whereas patients with more advanced stages of the disease polarized towards strong Th2 
reactivity (Figure 11).  Not every patient reacted against each peptide, but their responses were 
consistently polarized in accordance with the patient’s disease stage.  
We had access to one set of matched blood samples from an HLA-DR4+ patient pre- and 
post-therapy.  This individual had been rendered free of disease after surgery.  While the CD4+ T 
cells from this donor were Th1-biased before and after surgery, the frequency of IFN-γ spots 
associated with T cell responses against the EphA253-68 and EphA263-75 (but not the EphA2663-677) 
epitopes increased post-treatment (Figure 12).  This donor was also HLA-A2 and we observed 
that increased Th1-type CD4+ T cell-mediated immunity to EphA2 occurred in concert with 
increased frequencies of circulating IFN-γ secreting anti-EphA2 CD8+ T cells in this patient (i.e. 
Figure 9; filled circles). 
 
3.4.5. TGF-β and IL-10 production from RCC patient CD4+ T cells against EphA2 
peptides 
To evaluate whether Th3/Tr1 CD4+ T cells were present in the peripheral blood of RCC 
patients, we measured TGF-β and IL-10 production following in vitro peptide-stimulation.  
TGFβ1 production by responder CD4+ T cells was only observed in a subset (i.e. 3 of 8) of 
Stage IV patients (Figure 13) and notably, these same patients displayed coordinately weak Th1- 
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or Th2-type (IFN-γ and IL-5 ELISPOT) CD4+ T cell reactivity against EphA2 peptides.  IL-10 
production (above the detection limit of the ELISA) was not observed for any specimen tested.  
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 3.5. DISCUSSION 
The molecular definition of tumor-associated antigens has facilitated the development of 
immunotherapies designed to prime and boost tumor-specific T cell responses in cancer patients.  
In concert with these advances, cytokine release assays provide a powerful means to monitor the 
specificity and magnitude of evolving anti-tumor CD8+ and CD4+ T cell responses in the 
peripheral blood of patients before, during and after treatment (190). 
The major finding of our present study is a demonstration that patients with RCC exhibit 
detectable CD4+ and CD8+ T cell reactivity towards the receptor tyrosine kinase EphA2 that is 
aberrantly expressed at a high frequency in RCC tumors.  EphA2-specific CD8+ T cell activity is 
inversely proportional to the presence of active disease in these patients and is increased within 6 
weeks following therapeutic intervention that result in disease-free status.  Interestingly, two 
HLA-A2+ patients with Stage IV disease were identified who were long-term survivors (> 40 
months) post-surgery.  Both of these individuals displayed elevated peripheral blood frequencies 
of IFN-γ-secreting CD8+ T cells reactive against EphA2-derived epitopes.  It is tempting to 
hypothesize that the continued maintenance of high anti-EphA2 CD8+ T cell activity in these 
patients relates to their continued survival with active disease. 
Somewhat in contrast with the CD8+ T cell results, we have also shown that a fine balance 
of patient Th1-type versus Th2-type CD4+ T cell responses to EphA2 peptides can distinguish 
between disease-grades.  In particular, the most advanced forms of RCC tend to polarize towards 
Th2- or Tr-type anti-EphA2 responses.  This polarization in functional CD4+ T cell 
responsiveness, combined with the potential suppressive activity mediated by T regulatory cells 
in patients with Stage IV disease, may play facilitating roles in disease progression. 
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Our findings are unique in part because they indicate that EphA2 may provide a much-
needed target antigen for the design of immunotherapies for RCC. First, EphA2 is strongly 
expressed by a large number of RCC specimens, including 22 of 24 (92%) RCC cell lines and 29 
of 30 (97%) RCC biopsy samples that we have evaluated to date (current report and data not 
shown).  These findings are consistent with evidence emerging from studies of other tumor 
types, which indicate that high levels of EphA2 expression are characteristic of many forms of 
cancers, including melanoma and breast, colon, esophageal, head and neck, prostate and lung 
carcinomas, among others (56, 61, 74, 141, 142, 144, 147).  If our present studies can be 
extended to these other clinical indications, EphA2-specific T cell activity could provide an 
opportunity for a broadly applicable therapeutic intervention for cancer. 
 Interestingly, CD8+ T cell reactivity against EphA2 peptides (as determined in IFN-γ 
ELISPOT assays) differed greatly between RCC patients with active disease and those patients 
rendered free of disease.  Yet, anti-EphA2 CD8+ T cell reactivity did not distinguish RCC 
disease stage.  One potential explanation for this finding is that RCC tumors may suppress the 
generation, functionality and durability of CD8+ T cell responses against EphA2 in situ.  This 
hypothesis is consistent with general tumor-associated immune suppression of peripheral CTL 
and NK cell activity, as has been previously reported (191).  Notably, CD8+ T cell reactivity 
against EphA2-derived epitopes significantly increased in the peripheral blood of three HLA-
A2+ patients with Stage I RCC after curative surgery.  In contrast, in a Stage IV patient, surgical 
intervention without “cure” did not change the low frequency of CD8+ T cell reactivity towards 
EphA2 peptides. These results are consistent with the requirement for tumor clearance in situ 
(i.e. termination of chronic (tumor) antigenic stimulation) to allow for elevation in functional 
Tc1-like anti-tumor CD8+ T cell responses (192, 193).  An alternative explanation is that 
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expansion or maintenance of EphA2-specific CD8+ T cell activity may require the concerted 
support of specific Th1-type responses or a shift of existing patient Th2-type or T suppressor-
type to Th1-type immunity, particularly in the advanced cancer setting (189). 
Th1-type biased CD4+ T cell response could only be observed in a subset of Stage I RCC 
patients, and Th2- or Tr-type biased CD4+ T cell responses were almost always observed in 
Stage IV RCC patients.  It is important to stress that polarization away from Th1-type immunity 
in patients with advanced stage disease was tumor-specific, since individuals with Stage IV 
disease responded to influenza- and EBV-derived T helper epitopes in a “normal” Th1-biased 
manner ((189) and data not shown).  
 While longitudinal data was available for only one HLA-DR4+ patient with Stage I 
disease, Th1-type immunity against at least some EphA2 epitopes was strengthened and EphA2-
specific, Th2-type responses lessened after surgical resection of the patient’s tumor.  These 
results are consistent with previous reports that in most cancers, the immune response is believed 
to be suppressed (or deviated) in advanced stage cancer patients.  Our results also suggest that 
the nature of CD4+ T cell responses against “late-stage” EphA2 peptides correlates with RCC 
disease stage.  This finding contrasts with our previous observations for CD4+ T cell responses 
against the “early-stage” MAGE-6 epitopes where disease-state, but not disease-stage 
correlations were noted (189). 
 Th3/Tr CD4+ T cell subsets may play dominant roles as antigen-specific T “suppressor” 
cells, in part due to secretion of immunosuppressive cytokines such as TGF-β and/or IL-10 (54).  
Based on our detection of TGF-β (but not IL-10) production in 3 of 8 (38%) patients with Stage 
IV disease, it is tempting to speculate that the population of human CD4+CD25+ T suppressor 
cells may hinder the patient’s ability to productively eliminate EphA2-overexpressing tumors 
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(194).  These same patients failed to exhibit discernable Th1-type or Th2-type reactivity to 
EphA2 peptides, supporting the overall suppressive dominance of EphA2-specific T suppressor-
type immunity over specific Th1- or Th2-type responses.  These results suggest that Th2- or T 
suppressor-type responses are prevalent against EphA2 epitopes in advanced Stage RCC patients 
and likely contribute to the hyporeactivity of tumor-specific cellular immunity noted in these 
individuals.  Future studies could test this hypothesis using flow cytometric analyses to detect 
HLA-DR4/EphA2 peptide tetramer binding and co-expression of CD25, CTLA-4 or the 
glucocorticoid-induced tumor necrosis factor receptor (as markers of T suppressor cells, (194)). 
 EphA2-derived epitopes have potential to serve as components of a cancer vaccine.  
Unlike MAGE-6 reactive T cells, which are skewed toward Th2-type responses in early-stage 
disease (189), the imbalance in Th reactivity associated with EphA2 does not appear to occur 
until later-stage disease.  Hence, EphA2-based adjuvant vaccination of Stage I patients could 
have utility for eliciting protective immunity in patients at high risk for disease recurrence or to 
prevent prospective metastases.  Vaccination with both EphA2-derived CD4+ and CD8+ T cell 
epitopes may prompt high frequency anti-EphA2 CTL induction that is stabilized by the 
concurrent activation of specific Th1-type CD4+ T cells. Alternatively under appropriate re-
polarizing or activating conditions (195), dendritic cell-based vaccines incorporating EphA2 
peptides may allow for previously muted Th1-type immunity to be functionally “resurrected” in 
patients with advanced stage disease, yielding potential therapeutic benefit.  We are currently 
developing autologous DC/EphA2-based vaccines for the treatment of patients with renal, 
melanoma, prostate, head and neck or pancreatic cancer at the University of Pittsburgh Cancer 
Institute and the Cleveland Clinic Foundation. 
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Preface Chapter 4 
 Given that EphA2 epitopes are recognized by both CD8+ and CD4+ T lymphocytes, we 
next investigated whether or not we could modulate the expression of EphA2 protein in EphA2+ 
tumor cell lines, and whether this modulation could enhance the recognition of these tumor cells 
by anti-EphA2 CTLs.  We utilized two EphA2 agonists, B61.Ig and mAb208, to induce the 
degradation of overexpressed EphA2 protein in several EphA2+ tumors cell lines.  This agonist 
treatment resulted in the conditional induction of EphA2 phosphorylation and consequent 
degradation of EphA2 protein.  EphA2 degradation was determined to be proteasome-dependent, 
as the addition of MG132 inhibited EphA2 destruction.  Notably, the triggering of EphA2 
degradation by B61.Ig or Ab208 resulted in enhanced recognition by a CD8+ T-cell clone 
specific for EphA2883-91, supporting the ability of this conditional therapeutic strategy to sensitize 
EphA2 overexpressing tumor cells to immune surveillance. 
 The studies in Chapter 4 demonstrate our ability to modulate the proteasome-dependent 
processing of EphA2 protein in tumor cells, thereby supporting such manipulation as a potential 
immunotherapeutic protocol for the treatment of patients harboring EphA2+ tumors. 
  
 58
4. Conditional Triggering of Specific CD8+ T cell Recognition of EphA2+ Tumors 
After Treatment with Ligand Agonists 
Herrem, C.J.1, Tatsumi, T.2, Olson, W.C.1, Finke, J.H.4, Bukowski, R.M.4, Kinch, M.S.5
and Storkus, W.J.1,3,6
 
From the Departments of 1Immunology and 3Surgery, University of Pittsburgh School of 
Medicine, Pittsburgh, PA 15213, the 2Department of Molecular Therapeutics, Osaka University, 
Osaka, JAPAN 565-0871, the 4Cleveland Clinic Foundation, Cleveland, OH 44195, 
5MedImmune Inc., Gaithersburg, MD 20878, and the 6University of Pittsburgh Cancer Inst., 
Pittsburgh, PA 15213 
 
Running title:   RTK-Triggering Enhances CTL Recognition 
Key Words:  Renal Cell Carcinoma, EphA2, Receptor Tyrosine Kinase, Proteasome, 
CD8+ T Lymphocyte 
 59
 4.1. ABSTRACT 
 EphA2 is a receptor tyrosine kinase (RTK) that is overexpress at the protein level in a 
broad range of cancer types, where the degree of overexpression has been correlated with clinical 
prognosis.  We have previously reported that the EphA2 protein contains multiple peptide 
epitopes that can be recognized by effector CD4+ and CD8+ T cells isolated from normal donors 
and patients with cancer.  We have now evaluated whether the triggering of EphA2 
internalization using ligand agonists (B61-Ig and anti-EphA2 mAb 208) results in the 
proteasomal degradation of EphA2 and an increased T cell recognition as a result of peptide 
loading into HLA class I molecules. We report that both ligand agonists promote EphA2 
phosphorylation and consequent degradation that could be blocked by the proteasome inhibitor 
MG-132, but not by chloroquine.  While ligand agonist treatment had no effect on MHC class I 
expression, treated tumor cells were recognized significantly better than control, untreated tumor 
cells by a CD8+ T cell clone specific for the HLA-A2-presented EphA2883-891 epitope.  These 
results suggest that agonist treatments that promote EphA2 degradation may not only result in 
decreased proliferation and tumorigenic potential of EphA2+ tumors, but also their increased 
recognition by the EphA2-specific T cells. 
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4.2. INTRODUCTION 
 
The Eph family of molecules contains 14 members, comprising the largest known family 
of receptor tyrosine kinases (RTK) (1).  Based on sequence similarity and binding affinities, two 
classes of receptors have been defined, EphA and EphB.  There are 8 members of the EphA 
receptor family (EphA1 – EphA8) that primarily bind 5 ephrin-A ligands (ephrinA-1 – ephrinA-
5).  Ephrin-A ligands are attached to the cell surface via glycosylphosphotidylinositol (GPI) 
anchors and generally bind only to EphA receptors (196).  There are 6 members of the EphB 
receptor family (i.e. EphB1 – EphB6).  The EphB receptors primarily bind ephrin-B ligands (i.e. 
ephrinB1 – ephrinB3) which are transmembrane proteins (11). 
One Eph receptor, EphA2, is of particular interest due to recent evidence suggesting it 
may play a role in the development and progression of cancer.  EphA2 is a 130kDa (Type-1) 
glycoprotein that is expressed at low levels on many normal epithelial tissues (30).  In normal 
adult tissues, EphA2 is localized at epithelial cell-to-cell contacts, and is believed to play a role 
in contact inhibition of cell growth and motility (36, 57).  Hence not surprisingly, dysregulation 
in EphA2 expression and function has been linked to tumor progression and metastasis (56, 60, 
144, 146, 147, 197, 198).  EphA2 protein has been reported to be overexpressed 10-100 fold in 
metastatic prostate carcinoma cells when compared to non-invasive prostate epithelial cells (56), 
and is also expressed in greater amounts in malignant mammary tissue when compared to benign 
mammary epithelia (57, 58)  Zelinski, et. al. have further reported that forced overexpression of 
EphA2 cDNA via transfection was sufficient to confer malignant transformation on MCF-10, a 
benign human mammary epithelial cell line.  Given its overexpression on multiple epithelial 
based tumors, EphA2 can be considered a general, shared tumor associated antigen (TAA). 
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Previously, we have characterized EphA2 epitopes recognized by CD8+ and CD4+ T 
cells isolated from normal HLA-A2+ and/or –DR4+ donors and patients with renal cell 
carcinoma (RCC) (148).  We also documented that EphA2 is expressed in greater amounts in 
higher stage RCC (Stage IV vs. Stage I) and in metastatic RCC cell lines versus primary RCC 
lines.  Given this cumulative evidence demonstrating the association of EphA2 overexpression 
and dysregulation with carcinogenesis, its correlation with metastasis and its ability to be 
recognized by T-lymphocytes, EphA2 may represent a clinically important tumor antigen that 
should be targeted in immunotherapy applications designed for the treatment of patients with 
EphA2+ tumors. 
Since ligand agonists have been previously reported to promote receptor tyrosine kinase 
internalization (199, 200), we analyzed whether Ephrin-A1(B61)-Ig and anti-EphA2 mAb 
(Ab208) would promote the degradation of overexpressed tumor cell EphA2 via a mechanism 
leading to enhanced recognition of the treated tumor cell by EphA2-specific T cells.  We show 
that both B61-Ig and Ab208 promote rapid phosphorylation and consequent proteasome-
dependent degradation of EphA2 protein and that tumor cells treated in this manner elicit 
stronger responses from an anti-EphA2 specific CD8+ T cell clone.  Such conditional 
augmentation of tumor cell recognition by ligand agonist treatment in concert with active 
immunization against EphA2 epitopes or the adoptive transfer of EphA2-specific T cells may 
represent a novel and effective clinical strategy  for the treatment of  patients with EphA2+ 
malignancies.  
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4.3. MATERIALS AND METHODS 
 
4.3.1. Cell Lines and Media 
The T2.DR4 (HLA-A2+/-DRB1*0401+; (175)) cell line (kindly provided by Dr. Janice 
Blum, Indiana University School of Medicine, Indianapolis, IN) was used as the peptide-
presenting cell in ELISPOT assay.  The EphA2+ HLA-A2- PC-3 prostate carcinoma cell line 
was used as positive control for Western Blot analysis of EphA2 protein expression (56) and was 
also used as a negative control target in ELISPOT assays.  SLR24, an EphA2+ HLA-A2+ cell 
line was tested in western blot and ELISPOT assays.  All cell lines were maintained in RPMI-
1640 culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 
U/ml penicillin, 100 µg/ml streptomycin and 10mM L-glutamine (all reagents from GIBCO/Life 
Technologies, Grand Island, New York) in a humidified atmosphere under 5% CO2 tension at 
37°C. 
 
4.3.2. Western Blot Analyses 
Tumor cells were grown to 80-90% confluency, serum starved overnight, then treated with 
agonists where indicated.  Samples were analyzed for EphA2 expression via Western blots using 
the rabbit anti-human EphA2 polyclonal antibody (clone: C-20), Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA). Samples were also analyzed for Axl (clone C-20, Santa Cruz Biotechnology, 
Santa Cruz, CA) protein content.  Confluent flasks were lysed using 500µl lysis buffer (1% 
Triton –X, 150nM NaCl, 10mM Tris pH7.4, 1mM EDTA, .2mM SOV 0.5% NP-40)  in PBS 
containing protease inhibitors (Complete, Roche Diagnostic, Mannheim, Germany) for 30min at 
4°C. After centrifugation at 13,500 x g for 20 minutes, the supernatant was mixed 1:1 with SDS-
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PAGE running buffer and proteins separated on 7.5% PAGE gels, prior to electro-blotting onto 
nitrocellulose membranes (Millipore, Bedford, MA).  Blots were imaged on Kodak X-Omat Blue 
XB-1 film (NEN Life Science Products, Boston, MA) after using horseradish peroxidase (HRP)-
conjugated goat anti-rabbit Ig (Biorad, Hercules, CA) and the Western Lighting™ 
chemilluminescence  kit (PerkinElmer, Boston, MA).  Immunoprecipitation for EphA2 were 
performed using the anti-EphA2 antibody D7 (Upstate Biotech, Inc.).  Anti-phosphotyrosine 
antibodies (Clone pY99, Santa Cruz Biotechnology were used to assess pEphA2 content.  Mouse 
anti-β-actin antibodies (clone AC-15, Abcam, Cambridge, MA) were used as a loading control. 
 
4.3.3. EphA2 Agonists 
B61.Ig and mAb208 were obtained from Dr. Michael Kinch (MedImmune, Gaithersburg, 
MD).  B61.Ig is a chimeric protein consisting of the ligand binding domain of ephrin A-1 fused 
with the Fc portion of a mouse IgG antibody and was used at 30µg/ml where indicated.  mAb208 
is a mouse monoclonal antibody specific for EphA2 and was used at 8µg/ml where indicated. 
 
4.3.4. ELISPOT Assays 
ELISPOT assays for IFN-γ were performed as previously described (148).  CL.142, an 
HLA-A2+ CD8+ T cell clone specific for EphA2883-91, was generated as previously described 
(201).  CL.142 responses were evaluated by IFN-γ ELISPOT assays.  96-well multiscreen 
hemagglutinin antigen plates (Millipore, Bedford, MA) were coated with 10 µg/ml of anti-human 
IFN-γ mAb (1-D1K; Mabtech, Stockholm, Sweden) in PBS (GIBCO/Life Technologies) 
overnight at 4oC. Unbound antibody was removed by four successive washing with PBS. After 
blocking the plates with RPMI-1640/10% human serum (1hr at 37oC), 105 CD8+ T cells and 
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T2.DR4 cells (2 x 104 cells) pulsed with 10 µg/ml EphA2883-91 peptide (TLADFDPRV) or 
SLR24 +/- treatment overnight with B61.Ig were seeded in triplicate in multi-screen 
hemagglutinin antigen plates. Control wells contained CL.142 with T2.DR4 cells pulsed with 
HIV-nef190-198 peptide (AFHHVAREL) or PC3, an HLA-A2- EphA2+ tumor cell line, or 
T2.DR4 cells alone. Culture medium (AIM-V; GIBCO/Life Technologies) was added to yield a 
final volume of 200µl/well.  The plates were incubated at 37oC in 5% CO2 for 24 hr for IFN-γ 
assessments.  Cells were removed from the ELISPOT wells by washing with PBS/0.05% Tween 
20 (PBS/T). Captured cytokines were detected at sites of their secretion by incubation for 2 hr 
with biotinylated mAb anti-human IFN-γ (7-B6-1; Mabtec) at 2 µg/ml in PBS/0.5%BSA.  Plates 
were washed six times using PBS/T, and avidin-peroxidase complex (diluted 1:100; Vectastain 
Elite Kit; Vector Laboratories, Burlingame, CA) was added for 1 hr.  Unbound complex was 
removed by three successive washes using PBS/T, then with three rinses with PBS alone. AEC 
substrate (3-Amino-9-ethylcarbazol; Sigma, St. Louis, MO) was added and incubated for 5 min 
for the IFN-γ ELISPOT assay.  Spots were imaged using the Zeiss AutoImager (and statistical 
comparisons made using a two-tailed Student’s T-test.  We defined significance as a p value of 
less than or equal to 0.05. 
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4.4. RESULTS 
 
4.4.1. B61.Ig and mAb208 Induce EphA2 Phosphorylation in Tumor Cell Lines. 
 Proper EphA2 metabolism is dependent on the ability of the EphA2 to become activated 
and phosphorylated on cytoplasmic domain tyrosine residues, (i.e., Y588, Y594, Y772, Y921, as 
determined by GenBank). This allows for the RTK to become ubiquitinated and internalized, 
prior to being recycled to the cell surface or degraded via the proteasome.  In cancerous cells, 
this regulation can be disrupted resulting in RTK hypophosphorylation (65).  Indeed, the EphA2 
protein expressed in PC3 prostate carcinoma cells is constitutively underphosphorylated (Fig. 
14).  In order to determine whether treatment of PC3 with ligand agonists induces normalization 
in phosphorylation of EphA2, PC3 were treated with either B61.Ig or mAb208, and the 
phosphorylated EphA2 protein content was analyzed in Western Blots after immunoprecipitation 
of EphA2 protein.  As depicted in Figure 14, both ligands induced the rapid phosphorylation of 
EphA2 within 10-30 minutes of treatment. 
 
4.4.2. B61.Ig and mAb208 Induce the Proteasome-Dependent Degradation of Tumor 
Cell Expressed EphA2 Protein 
 
  To determine whether agonist ligands also promote EphA2 degradation, the EphA2+ 
prostate carcinoma cell line PC3 (56) and the RCC cell line SLR24 were each treated with 
B61.Ig or mAb208 for 6 hrs at 37°C, lysed, and EphA2 protein levels were assessed in Western 
Blots. The B61.Ig and mAb 208 treatment regimens were able to induce EphA2 degradation in 
both the PC3 and SLR24 cell lines (Figs. 15A, 15B, and data not shown), as well as additional 
EphA2+ carcinomas (including the pancreatic carcinoma PANC-3.27; data not shown), 
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suggesting the generality of these findings.  EphA2 agonist effects were specific for EphA2, 
since protein expression levels of an alternate RTK overexpressed by these cell lines, AXL, 
remained unaltered in its protein expression level after treatment with these ligands (Figs. 15A, 
15B).  
To determine whether ligand-induced degradation of EphA2 was dependent on the 
proteasome, we repeated these assays in the presence of the 26S proteasome inhibitor MG-132.  
While MG-132 effectively blocked EphA2 degradation promoted by addition of B61-Ig or 
mAb208 (Fig. 16), the addition of the endosomal/lysosomal inhibitor chloroquine had no effect, 
supporting the proteasome-dependency of this event.   
 
 
4.4.3. EphA2 Agonist Treatment Enhances CD8+ T Cell Recognition of EphA2+ 
Tumors 
 Given that EphA2 can be triggered to be degraded using EphA2 agonists on EphA2+ 
tumors via the proteasome, this could theoretically lead to an increase in EphA2 epitope 
presentation on MHC Class I molecules expressed by EphA2+ tumors and to tumor cell 
recognition by EphA2-specific CD8+ T cells.  To address this issue, we initially evaluated the 
effects of ligand agonist treatment on the expression of MHC Class I molecules on EphA2 
agonist treated EphA2+ tumor cells, using the SLR24 RCC cell line as a model.  Neither HLA 
Class I nor control antigen CD40 expression on SLR24 cells was affected by either treatment 
(Table 6). 
 To determine whether ligand agonist treatment of EphA2+ tumors results in enhanced 
recognition by specific CD8+ T cells, non-treated or B61-Ig treated SLR24 cells were analyzed 
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as stimulators for the  EphA2883-91 specific CTL clone 142 (CL.142) in IFN-γ ELISPOT (Fig. 
17).  Pretreatment of SLR24 with B61.Ig significantly enhanced CL.142 recognition of SLR24 
relative to untreated control cells.  
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4.5. DISCUSSION 
 In this study, we report that the administration of specific ligand agonists to EphA2 
overexpressing pancreatic, prostate and RCC cell lines induces the phosphorylation and 
proteasome-dependent degradation of EphA2 This treatment regimen did not affect the 
quantitative level of MHC Class I or CD40 expression on EphA2+ tumor cell lines.  However, 
treated tumor cell lines elicited increased reactivity from cloned EphA2-specific CD8+ T-cells.  
These findings suggest that the use of EphA2 agonists may represent a new modality for 
consideration as a single agent or a component in combinational immunotherapies due to their 
capacity to conditionally sensitize EphA2+ tumor cells to specific CD8+ T cell reactivity.   
The activation of EphA2 and other RTK is necessary for their proper function and 
metabolism.  In normal epithelia, EphA2 is located at cell-to-cell boundaries, and it is generally 
believed that one of the major functions of this RTK is to maintain cell-to-cell contacts and to 
limit epithelial cell growth. This is critical for the organization and formation of epithelial layers 
in EphA2+ tissues.  Normal activation of EphA2 results in the de-phosphorylation of focal 
adhesion kinase (FAK), which in turn suppresses integrin function (35),  and limits the ability of 
EphA2+ epithelial cells to make contacts with the extracellular matrix (ECM).  However, when 
EphA2 expression becomes dysregulated, affected cells become more invasive, at least in part, 
due to an increase in cellular contacts formed with the ECM (61).  This appears to be a common 
event in tumor metastases, where EphA2 is frequently dysregulated and overexpressed (197).  
Under such conditions, EphA2 ligand agonists can restore a normalized pattern of contact 
inhibited growth and reduce the invasiveness of EphA2+ tumor cells (199).  
The phosphorylation of the EphA2 after interaction with ligand agonists promotes the 
association of EphA2 with c-Cbl (62).  C-cbl contains an internal SH2 domain, which allows for 
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it to bind to phosphorylated RTKs.  It also contains an ubiquitin-E3 ligase which is responsible 
for the addition of ubiquitin molecules to the respective RTK.  This targets proteins for 
degradation via the proteasome and/or for sorting within the endosomal/lysosomal pathway 
(202).  This is a major pathway in the recycling of EphA2 and RTK after they have signaled as a 
consequence of engaging their ligands.  In this pathway, internalized, activated EphA2 molecules 
that become dephosphorylated are recycled to the cell membrane, while those that remain 
phosphorylated undergo proteasome-dependent degradation.  In the context of our studies, this 
results in the consequent MHC class I presentation of EphA2-derived peptides, such as EphA883-
891 to specific CD8+ T cells. 
The finding that dysregulated tumor-overexpressed EphA2 is hypophosphorylated is 
consistent with reports of frequent co-ordinate overexpression of regulatory protein tyrosine 
phosphatases in cancer cells that may serve to inactivate phospho-EphA2 species quickly after 
they are formed. Recently, it has been reported that low molecular weight-protein tyrosine 
phosphatase (LMW-PTP) is overexpressed in many cancer types (70, 203), and that EphA2 is a 
major substrate for this enzyme (67).  This increased expression and function of LMW-PTP, 
along with other intracellular phosphatases, i.e. PTP-1B (204, 205), may contribute to the 
accumulated overexpression of EphA2, as well as other tumor-associated RTKs. The use of 
phosphatase inhibitors on EphA2+ tumors could possibly result in restoration of EphA2 
phosphorylation, proteasomal processing and MHC-presentation.  This theory is currently being 
evaluated in our laboratory. 
In summary, the ability to conditionally trigger EphA2 degradation and the presentation 
of its derivative peptide epitopes in MHC complexes offers new hope for the improved efficacy 
of combinational immunotherapy approaches.  Ideally, such therapies would take the form of an 
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EphA2-based vaccine that can activate specific CD8+ T cells that could then be directed to more 
effectively recognize and eradicate EphA2+ tumor cells in situ after the administration of EphA2 
ligand agonists. Alternatively, ex vivo expanded EphA2-specific CD8+ T cells could be 
adoptively transferred into patients that are co-treated with EphA2 ligand agonists. 
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Preface Chapter 5 
 Since overexpression of protein tyrosine phosphatases has been reported in certain cancer 
settings, and these enzymes appear to regulate the magnitude of RTK phosphorylation and 
consequent proteolytic processing, we next explored whether phosphatase inhibitors augmented 
EphA2 degradation in RCC cell lines in vitro.  We observed that EphA2 was constitutively 
underphosphorylated in EphA2+ tumors, but that the addition of protein tyrosine phosphatase 
inhibitor-2 (PTP I-2) rapidly reversed this condition and induced the phosphorylation of EphA2 
in the PC3 prostate carcinoma cell line.  Furthermore, we observed that treatment of tumor cells 
with PTP I-2 (or a range of other phosphatase inhibitors) also induced the co-ordinate 
degradation of additional overexpressed RTKs including the epidermal growth factor receptor 
EGFR (erbB-1) and Axl.  
 The results in Chapter 5, in conjunction with the results in Chapter 4, provide the 
foundation for the development of novel combinatorial therapies implementing RTK agonists 
and phosphatase inhibitors to promote the conditional processing and MHC presentation of 
RTK-derived peptide epitopes for immune cell recognition.  Furthermore, by reducing EphA2 
(and other RTK) protein expression, the immune system will be targeting less aggressive tumors 
in situ, which may further accentuate the efficacy of this approach.  
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5.1. ABSTRACT 
EphA2 is a novel oncoprotein that is overexpressed in a wide range of cancer types, where 
it is linked to metastatic potential and poor clinical prognosis.  Cancer cell overexpression of 
EphA2 appears linked to the inability of this receptor tyrosine kinase to become phosphorylated 
for a sufficient period of time to allow for its consequent degradation in neoplastic cells.  Since 
instability in phosphorylated EphA2 species may be regulated by cellular phosphatases that have 
also been reported to be overexpressed in cancer, we studied whether the inhibition of cellular 
phosphatases would result in the conditional augmentation in EphA2 phosphorylation and 
proteasome-dependent degradation in EphA2+ tumor cell lines in vitro.  Treatment of tumor cells 
with the nitric oxide donor NO-PAPA, or the PTP-inhibitors sodium orthovanadate and protein 
tyrosine phosphatase inhibitor-2, but not the protein serine/threonine phosphatase inhibitor 
okadaic acid, resulted in the efficient degradation of EphA2 protein.  Interestingly, this affect 
was not restricted to EphA2, as two additional tumor cell expressed RTKs, Axl and EGFR/erb1, 
were also induced by these PTP inhibitors to undergo degradation. . Furthermore, by treating 
tumor cells with the anti-EphA2 agonist mAb208 (that promotes phosphorylation of EphA2) and 
NO-PAPA (to block PTPs), we observed an additive effect on conditional EphA2 degradation.  
These results confirm the dependency of EphA2 (and other RTK) degradation on PTPs and 
suggests that clinical application of combinatorial therapies using RTK agonists and PTP 
inhibitors may exhibit efficacy by limiting the oncogenic effects of RTKs in cancer cells. 
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5.2. INTRODUCTION 
We have previously identified EphA2 as a novel tumor antigen in the setting of renal cell 
carcinoma (148).  Although EphA2 overexpression had been reported by others in prostate and 
lung cancers, the mechanism(s) underlying the overexpression/accumulation of this protein had 
not been resolved.  EphA2 belongs to the largest known family of receptor tyrosine kinases 
(RTK, (1)), and is believed to play a major role in the contact growth inhibition of epithelial cells 
(36).  The regulation of RTKs has been studied extensively given their reported effects in 
carcinogeneis (65, 148, 200, 204).  In normal cells, upon RTK interaction with a multivalent 
ligand, the RTK becomes autophosphorylated on cytoplasmic tyrosine residues.  This 
phosphorylation promotes the association of pRTKs with c-Cbl, an ubiquitin E3-ligase.  
Ubiquitinated pRTKs are then internalized and sorted in intracellular endosomal/lysosomal 
compartments, with a fraction of RTKs recycled to the plasma membrane and a fraction targeted 
for proteasome-dependent degradation (202).  The sorting decision for recycling vs. degradation 
appears related to both the stability of the state of RTK phosphorylation and the degree of 
polyubiquitination (202).  Perturbation of c-Cbl function or RTK phosphorylation each result in 
dysregulation in RTK homeostasis and overexpression/accumulation of these proteins in affected 
cells (206). 
A major regulator of RTK metabolism is the family of protein tyrosine phosphatases 
(PTPs; (204, 207).  PTP play major regulatory roles in dictating the cellular fate of activated 
pRTK.  PTP are responsible for the removal of phosphate groups added to pRTK when they have 
been appropriately activated via physiologic ligands binding to the RTK extracellular domain 
(69, 70, 205, 208).  The balance of phosphotyrosine content in activated RTK species is critical 
in determining the fate of these molecules.  For instance, if the pRTK is de-phosphorylated, 
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interactions with c-Cbl are prevented and the RTK is not ubiquitinated or internalized, resulting 
in its accumulation on the cell surface.  Recently, several groups have reported that PTPs are 
frequently overexpressed in a diverse array of cancer types (70, 207).  In particular, it has been 
reported that the low molecular weight-protein tyrosine phosphatase (LMW-PTP) is 
overexpressed in several cancers (70) and that EphA2 is a substrate for the LMW-PTP, giving 
credibility to the potential role of LMW-PTP in indirectly regulating tumor cell growth and 
invasiveness by dysregulating RTK expression/function 
Given our existing knowledge that agonist (ligand) induction promotes the 
phosphorylation and subsequent degradation of EphA2 (Chapter 4), this chapter explores the 
hypothesis that the inhibition of cellular phosphatases may restore normal phosphorylation and 
metabolism of EphA2 in tumor cell lines.  We show that the inhibition of PTP, but not protein 
serine/threonine phosphatases through a variety of pharmacologic inhibitors results in increased 
EphA2 phosphorylation and consequent degradation.  Furthermore, we noted that ligand agonists 
and PTP inhibitors acted additively in promoting EphA2 proteolysis.  These results confirm the 
notion that the dysregulation of EphA2 phosphorylation is a major factor in EphA2 
overexpression and provide a model for developing novel therapeutics that may block the 
malignant characteristics of RTK overexpression in cancer cells. 
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5.3. MATERIALS AND METHODS 
5.3.1. Cell Lines and Media 
The EphA2+ HLA-A2- PC-3 prostate carcinoma cell line was used as positive control for 
Western Blot analysis of EphA2 protein expression (56).  SLR24, an EphA2+ HLA-A2+ cell 
line and Panc 3.27, a pancreatic carcinoma cell line were also tested in PTP inhibition studies.  
All cell lines were maintained in RPMI-1640 culture medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 10mM 
L-glutamine (all reagents from GIBCO/Life Technologies, Grand Island, New York) in a 
humidified atmosphere under 5% CO2 tension at 37°C. 
 
5.3.2. Pharmacologic PTP Inhibitors 
NO-PAPA was obtained by a generous gift from Dr. Lawrence Keefer (National Cancer 
Institute, Bethesda, MD).  Sodium orthovanadate, phenylarsine oxide, levamisole, and okadaic 
acid were all obtained from Sigma-Aldrich (St. Louis, MO).  PTP Inhibitor-2 was obtained from 
EMD Biosciences (San Diego, CA).  All pharmacologic agents were used per the manufacturer’s 
instructions and applied as indicated in figure legends. 
 
5.3.3. Western Blot Analyses 
Tumor cells were grown to 80-90% confluency, serum starved overnight, then treated with 
agonists where indicated.  Samples were analyzed for EphA2 expression via Western blots using 
the rabbit anti-human EphA2 polyclonal antibody (clone: C-20), Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA). Samples were also analyzed for Axl (clone C-20, Santa Cruz Biotechnology, 
Santa Cruz, CA) and EGFR (clone 1005, Santa Cruz Biotechnology, Santa Cruz, CA).  
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Confluent flasks were lysed using 500µl lysis buffer (1% Triton-X100, 150nM NaCl, 10mM Tris 
pH7.4, 1mM EDTA, .2mM SOV 0.5% NP-40)  in PBS containing protease inhibitors (Complete, 
Roche Diagnostic, Mannheim, Germany) for 30min at 4°C with agitation. After centrifugation at 
13,500 x g for 20 minutes, the supernatant was mixed 1:1 with SDS-PAGE running buffer and 
proteins separated on 7.5% PAGE gels, prior to electro-blotting onto nitrocellulose membranes 
(Millipore, Bedford, MA).  Blots were imaged on Kodak X-Omat Blue XB-1 film (NEN Life 
Science Products, Boston, MA) after using horseradish peroxidase (HRP)-conjugated goat anti-
rabbit Ig (Biorad, Hercules, CA) and the Western Lighting™ chemilluminescence  kit 
(PerkinElmer, Boston, MA).  Immunoprecipitation for EphA2 were performed using the anti-
EphA2 antibody D7 (Upstate Biotech, Inc.).  Anti-phosphotyrosine antibodies (Clone pY99, 
Santa Cruz Biotechnology were used to assess pEphA2 content.  Mouse anti-β-actin antibodies 
(clone AC-15, Abcam, Cambridge, MA) were used as a loading control.  Densitometric 
visualization was done using a White/UV Transilluminator (UVP Products, Upland, CA) and 
analysis performed using Labworks (UVP) software.  Statistical comparisons of protein content 
were made using a two-tailed Student’s T-test.  We defined significance as a p value of less than 
or equal to 0.05. 
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5.4. RESULTS 
5.4.1. NO-PAPA Induces EphA2 Degradation 
 
Amid reports that nitric oxide (NO) metabolites (e.g. peroxynitrites) are able to inhibit 
LMW-PTP (209), and that LMW-PTP can use EphA2 as a substrate, we initially chose to 
evaluate whether the addition of NO to EphA2+ tumors could induce EphA2 degradation.  We 
used NO-PAPA, a nucleophilic salt that upon addition to aqueous media releases NO (210), to 
test whether we could conditionally induce the degradation of EphA2.  PC3, an EphA2+ prostate 
carcinoma cell line, was treated for 6 hours, lysed, and EphA2 protein expression was assayed 
via western blot.  As shown in Figure 18, NO-PAPA was able to induce the degradation of 
EphA2 in a dose-dependent and non-toxic manner.  These results suggest that a known LMW-
PTP inhibitor (NO) can induce EphA2 degradation in tumor cell lines in vitro. 
We have reported previously (Chapter 4) that the addition of EphA2 agonists could induce 
the phosphorylation and subsequent degradation of EphA2.  We next tested whether or not the 
co-administration of both NO-PAPA and mAb208 could induce EphA2 degradation more 
efficiently than either reagent alone.  PC3 cells were treated with either NO-PAPA, mAb208, or 
both for 6hr, with EphA2 protein expression consequently analyzed via western blot.  Co-
treatment of tumor cells with NO-PAPA and mAb208 was able to promote significantly more 
EphA2 degradation than either NO-PAPA of mAb208 alone (Fig.19A; vs. NO-PAPA, p = .05; 
vs. mAb208, p =.015).  Interestingly, EphA2 was not the only RTK affected in this manner by 
NO-PAPA treatment.  Axl, another RTK family member that has also been implicated in cancer, 
was similarly induced to undergo degradation after treatment with NO-PAPA (Fig 19B).  These 
results raise the possibility that the inactivation of PTP may induce the coordinate degradation of 
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multiple, overexpressed RTKs in cancer cells, a process that may be further accentuated by 
inclusion of RTK agonist signals. 
 
5.4.2. PTP I-2 Induces the Phosphorylation of EphA2 
These findings suggested that inactivation of PTP may represent a relevant means through 
which RTK expression may be profoundly down-modulated.  However, since the effects of NO 
are pleiotropic, we wished to further clarify the relevancy of PPs in the observed effects on RTK 
expression.  Central to our hypothesis of PTP inhibition leading to RTK degradation is the 
restoration of tyrosine phosphorylation on RTK.  We tested a specific PTP inhibitor, protein 
tyrosine phosphatase inhibitor-2 (PTP I-2), for its ability to allow for EphA2 phosphorylation to 
occur in PC3 cells.  As shown in Fig. 20 addition of PTP I-2 to PC-3 cultured cells resulted in the 
rapid phosphorylation of EphA2 protein.  This same effect was also demonstrated in EphA2+ 
RCC (SLR24) and pancreatic carcinoma (PANC-3.27) cell lines, demonstrating the generality of 
these results in cancer cells of diverse histologic types (data not shown). 
 
5.4.3. PTP Inhibitors Induce RTK Degradation 
Given the result that PTP I-2 is able to induce EphA2 phosphorylation/degradation, we 
next wished to determine whether tumor cell treatment with other pharmacologic PTP inhibitors 
produced similar results.  We tested numerous PTP inhibitors (e.g. phenylarsine oxide (PAO), 
levamisole, Table 7) and focused our comparative analyses on sodium orthovanadate (SOV) vs. 
PTP I-2, since the other agents exhibited significant cellular toxicity.  As described above, PC3 
cells were treated for 6 hr with our candidate PTP inhibitors, lysed, and lysates were resolved via 
SDS-PAGE.  Using western blot assays (Fig. 21) both SOV and PTP I-2 were able to induce the 
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degradation of EphA2 (Fig. 21A).  Consistent our results in Fig 21A, these PTP inhibitors also 
induced the degradation of additional tumor cell-expressed RTKs, including Axl (Fig. 21B) and 
EGF-R (erbB-1) (Fig. 21C).  This process was clearly dependent on PTP and not general PP 
inhibition, as the addition of okadaic acid (OKA), a serine-threonine phosphatase inhibitor, had 
no effect on EphA2 protein expression (Fig. 22).  EphA2 induced degradation by PTP I-2 was 
able to be induced by lactacystin and chloroquine (Fig. 23)  The inhibition by chloroquine is 
interesting due to that PTP I-2 induced RTK degradation may increase RTK epitope presentation 
to CD4+ T cells.  These results as a whole are significant since they support a novel and 
translatable strategy for the conditional promotion of RTK protein down-regulation and 
processing through the use of PTP inhibitors.  This provides clinicians with a novel therapeutic 
tool for potential implementation in the treatment of numerous types of cancers. 
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5.5. DISCUSSION 
We have shown that PTP inhibitors restore EphA2 phosphorylation in EphA2+ tumor cell 
lines and induce its degradation.  Interestingly, this observation was true not only of EphA2, but 
two other RTK (Axl, EGFR/erb1) family members that were more effectively degraded in the 
presence of PTP inhibitors.  This is consistent with phosphorylation being a rate-limiting 
requirement for proper RTK metabolism.  The inhibition of PTP and restoration of EphA2 
phosphorylation supports our hypothesis that the lack of proper EphA2 phosphorylation is a 
major mechanism for EphA2 overexpression in cancer cells. 
As we have previously demonstrated in Chapter 4, EphA2+ tumors are sensitized to 
recognition by CTL after treatment with EphA2 ligand agonists.  Hence, it is possible that the 
treatment of RTK+ tumor cells with PTP inhibitors (alone or with ligand agonists) will similarly 
lead to enhanced RTK-specific immune recognition of these conditionally manipulate target 
cells.  If validated, this would provide a compelling strategy to enhance tumor cell sensitivity to a 
broad repertoire of tumor-reactive T effector cells that would be restricted by multiple patient 
MHC molecules. As such, this approach would circumvent current limitations in 
immunotherapies using synthetic tumor antigen-derived peptide epitopes that are relevant in only 
a subset of patients with cancer.  We are currently assessing this hypothesis in our laboratory. 
Currently, PTP inhibitors are being used clinically (i.e. nitroprusside, orthovanadate) for 
the treatment of hypertension.  Pending dose-limiting toxicities, the use of PTP inhibitors could 
be readily translated into cancer therapeutic protocols.  In conjunction with EphA2 agonists, the 
use of PTP inhibitors could provide a novel combinatorial therapeutic approach to the treatment 
of EphA2+ tumors.  Our demonstration that PTP inhibitors induce the degradation of additional 
RTKs (Axl, EGFR), and our and others reports that EGFR/erb1 and HER2/neu undergo 
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degradation after treatment with anti-RTK mAbs (Appendix A), suggest that the coordinate 
application of RTK agonists and PTP inhibitors could prove clinically beneficial to patients 
presenting with a wide range of tumors the overexpress RTKs. 
 83
6. SUMMARY AND CONCLUSIONS 
While vaccines based on whole tumor cell vaccines have been applied clinically for the 
past several decades, this approach has proven marginally effective in the treatment of cancer 
patients and provided minimal mechanistic insight into either the specificity of clinically-
important T cells or biochemical pathways in tumor cells that may be exploited for therapeutic 
gain.  We believe that the molecular characterization of tumor antigens and their derivative 
epitopes is necessary for optimal therapy benefit to be derived from vaccine strategies designed 
to elicit specific CD4+ and CD8+ T cells in the setting of cancer.  In these studies, we have 
focused our efforts on the characterization of a novel tumor antigen, EphA2.  EphA2 
overexpression has been repeatedly reported in numerous cancer settings, and is also correlated 
with metastatic disease and tumor neoangiogenesis.  We set out to define T cell epitopes 
recognized by both CD8+ and CD4+ T lymphocytes.  In addition, we were also interested in 
determining the functional CD4+ T cell response to EphA2 epitopes as it relates to cancer 
staging.  We had the good fortune of having archived tissue microarrays (TMA) that also 
allowed us to analyze the expression of EphA2 in resected RCC biopsy specimens in order to 
determine if the relative expression of EphA2 was predictive of the time to disease recurrence in 
RCC patients.  Finally, we studied whether or not the modulation of EphA2 degradation in tumor 
cell lines that overexpress this antigen resulted in improved proteasome-dependent processing of 
this protein and improved recognition of treated tumor cells by specific CTLs.   In these studies, 
we have efficiently defined and characterized a novel tumor antigen that we believe should now 
be targeted by new treatment strategies for the more effective management of EphA2+ tumors. 
 
 The initial phase of my studies involved analyzing the expression of EphA2 protein in 
tumor biopsies excised from patients with RCC.  We were interested in determining whether the 
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level of EphA2 protein expression on primary tissue samples was predictive of the time to 
recurrence in the evaluated patients.  Tissue microarrays (TMA) containing patients with 
recurrence intervals of months to more than 17 years were assessed for relative EphA2 
expression levels by immunohistochemistry.  We noted a strong correlation between the degree 
of expression of EphA2 protein in the excised lesions and the time to recurrence of RCC disease.  
Patients that exhibited a high protein expression of EphA2 (ave. score = 3.81) were more likely 
to experience disease recurrence in less than 1 year.  This was significant when they were 
compared to patients who exhibited lower levels of EphA2 protein expression.  These latter 
patients experienced RCC disease recurrence only after 1 year of resection.  While the average 
score for EphA2 expression was lower for the cohort of patients who recurred 5 or more years 
(ave score = 1.27) after surgery versus patients who recurred between 1 and 5 years (ave score = 
1.6) post-treatment, this difference was not statistically significant.  We further noted that tumors 
displaying higher levels of EphA2 expression tended to be more vascularized as determined by 
the density of Factor VIII+ vessel staining.  This suggests the relative level of EphA2 expression 
may be associated with, or represent a surrogate marker for tumor neoangiogenesis in RCC, as 
has been recently intimated in the setting of colorectal carcinoma.  RCC tumors expressing high 
levels of EphA2 protein also tended to be larger in volume when compared to low EphA2 
expression RCC tumors.  These results support the hypothesis that EphA2 is a major factor in 
tumor progression and may promote the metastatic capacity of tumor by enhancing access to the 
circulatory system and promoting a more invasive/aggressive form of the disease.  With respect 
to RCC, EphA2 overexpression should be considered as a relevant negative prognostic indicator 
and should be contemplated for adoption in the clinical management of patients with RCC (i.e. 
the more aggressive treatment of patients with lesions overexpressing EphA2 and/or more 
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frequent follow-up of surgically cured patients whose resected lesions were high EphA2 
expressors). 
Next, we wished to analyze the protein expression of various primary and metastatic RCC 
cell lines available in our laboratory to test the hypothesis that EphA2 expression is correlated 
with metastatic disease.  We confirmed this hypothesis by using immunohistochemistry and 
western blot analysis demonstrating the positive correlation between RCC overexpression and 
metastatic phenotype.  Metastatic RCC cell lines expressed more EphA2 compared to primary 
RCC cell lines, and both of these groups expressed more EphA2 compared than the HK2, a 
normal human kidney cell line.  This correlation with metastasis was also observed in RCC 
tissue samples where EphA2 protein expression was assessed immunohistochemically.  Stage IV 
RCC samples expressed considerably more EphA2 protein when compared to Stage I RCC 
tissues. 
The next phase of our studies was to define T cell epitopes contained within EphA2, and to 
assess whether those epitopes were differentially recognized by T cells isolated from normal 
donors and patients with RCC.  In order to evaluate T cell specificity for EphA2 epitopes, we 
chose to utilize a DC in vitro based method to assess T cell specificity for EphA2 peptides using 
cytokine-specific ELISPOT assays.  T lymphocytes isolated from both normal donors and 
patients with RCC were able to recognize both the (5) HLA-A2- and (3) HLA-DR4-presented 
epitopes that we identified based on motif analyses performed using net-based predictive 
algorithms.  Of critical importance, in vitro generated EphA2-specific T cells were also able to 
recognize EphA2+ tumors in both HLA-A2- and HLA-DR4-restricted manners, confirming that 
our candidate epitopes were naturally processed and MHC-presented and are therefore, 
biologically relevant. 
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Given recent reports from our group, among others, suggesting a polarization in anti-tumor 
T cell responses away from the Tc1/Th1-type in cancer bearing individuals, we were keen to 
assess the functionality of anti-EphA2 T cells and whether any Type-1 vs. Type-2 or T-
regulatory biases would be observed and whether these would be correlated with the presence of 
disease or disease stage in patients with RCC.  With respect to CD8+ T cell functionality, 
patients who had no evidence of disease (NED) after tumor excision or who were long term 
survivors (LTS) exhibited a Tc1 response (IFN-γ production) to HLA-A2-presented EphA2 
epitopes.  Patients who still had residual disease after tumor excision or who had active RCC 
disease did not produce detectable levels of IFN-γ in response to EphA2 epitopes.  Interestingly, 
we were able to test several RCC patients before and after their surgical treatment for RCC and 
noticed that after surgery (within 6 weeks post-surgery), patients who had previously 
demonstrated Type-2 immunity against EphA2 epitopes, were now able to produce Type-1 
CD8+ T cell responses to this antigen.  This data supports the notion that EphA2+ tumors may 
adversely affect the immune system.  This may be due to the production of Th1-inhibiting 
cytokines (e.g. IL-5, IL-10, TGF-β) by RCC.  The recognition of EphA2+ TCC tumors in this 
tumor microenvironment would skew the T cell away from producing the necessary cytokines 
(i.e. IFN-γ) required for cell-mediated immune clearance of EphA2+ tumors.  The (at least 
temporary) restoration of Type-1 immune responses against EphA2 epitopes after the surgical 
removal of RCC supports this hypothesis. 
Similar results were obtained when CD4+ T cell functionality was assessed in patients with 
RCC disease.  The CD4+ T cell immune response in patients with Stage IV RCC disease was 
skewed towards Th2-type immune responses, where patients with Stage I disease exhibited Th1-
type immunity against EphA2.  For those patients where pre- and post- surgery samples were 
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available, the ratio of Th1(IFN-γ):Th2(IL-5) cytokines production in response to EphA2 epitopes 
was significantly increased when RCC tumors were excised from diseased patients. 
We also tested the supernatants of cultured CD4+ T cells from RCC patients in order to 
assay for the presence of Th3/Treg-type suppressor CD4+ T cells.  Th3- and Treg-type 
“suppressor” T cells produce immunoregulatory cytokines (e.g. IL-10, TGF- β) in order to 
temper the immune response by preventing overactive inflammatory immune responses.  
Hypothetically, tumors may impact the immune response by influencing CD4+ T cells to become 
functionally Th3-like.  By using cytokine-specific ELISA assays, we confirmed this hypothesis 
by detecting TGF-β production in the supernatants of CD4+ T cells stimulated with EphA2 
peptides, although these responses were observed in only a minority of Stage IV RCC patients.  
Thus, in addition to lacking Type-1 immune responses against EphA2 epitopes and exhibiting 
prevalent (and ineffective) anti-EphA2 Type-2 immunity, advanced stage RCC patients also may 
be clinically hampered due to the presence of Treg-type immunity against tumor antigens, such 
as EphA2.  If generalizable to most/all tumor antigen-specific responses, this active skewing in 
Th responses would provide the tumor a degree of “protection”, allowing for tumor growth to 
continue unchecked by the T cell immune response.  Given such subterfuge observed in specific 
T cell responsiveness in RCC patients, these results suggest that EphA2 is an important tumor 
antigen in the setting of RCC. 
After demonstrating that T cells (of moderate avidity) are able to recognize EphA2 epitopes 
expressed naturally by tumor cells, we explored whether or not we could modulate T cell 
recognition by conditional regulation of EphA2 processing in EphA2+ tumor cell lines.  With the 
positive correlation of EphA2 expression with metastasis, tumor neoangiogenesis, and a poor 
prognosis in certain cancer settings, a reduction in EphA2 protein expression levels on tumors 
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may prove therapeutically beneficial by inhibiting EphA2-dependent tumor vascularization and 
the development of metastases.  In our initial series of experiments, we utilized two EphA2 
agonists, B61.Ig and the monoclonal antibody 208 (mAb 208) to assess whether or not EphA2 
crosslinking/activation could conditionally induce the degradation of EphA2.  Agonist addition 
to several different EphA2+ tumors induced the degradation of EphA2, while it did not affect the 
expression levels of other RTK family members (such as Axl, EGF-R, etc.).  EphA2 agonist 
treatment also had no effect on tumor cell expression of HLA Class I molecules or T-cell 
costimulatory molecules (e.g. CD40).  As is the case for other RTKs, the internalization of 
EphA2 is dependent upon the autophosphorylation of its intracellular domain.  As a possible 
mechanism underlying its overexpression in cancer cells, we hypothesized that the lack of proper 
tyrosine phosphorylation of EphA2 could be a major contributing factor.  We analyzed the 
phosphorylation content of EphA2 on PC3 prostate carcinoma cells and observed that EphA2 is 
constitutively underphosphorylated in this cell line.  Upon agonist treatment, however, EphA2 
rapidly became phosphorylated on at least one tyrosine residue, which was subsequently 
followed by degradation of the activated pEphA2 species. 
We next wanted to study whether such modulation of EphA2 protein expression would 
result in enhanced T cell immune responsiveness against EphA2+ tumors.  Indeed, the induction 
of EphA2 degradation would hypothetically result in the increased frequency of EphA2 epitopes 
presented on HLA Class I molecules by EphA2+ tumors, which could possibly enhance the 
recognition of EphA2+ tumors by CD8+ T cells.  With HLA Class I antigen processing being 
proteasome-dependent, we tested whether the inhibition of the proteasome would inhibit the 
degradation of EphA2 protein in conditionally triggered tumor cells.  By using the peptide 
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aldehyde proteasome inhibitor MG132, we were able to effectively inhibit EphA2 degradation 
induced by EphA2 agonists, demonstrating the proteasome dependency of this process. 
In order to test whether EphA2 agonist treatment could increase EphA2+ tumor cell 
recognition by CD8+ CTLs, we utilized an HLA-A2-restricted CTL clone specific for the 
EphA2883-91 (CL.142) epitope as an effector cell population.  By using ELISPOT assays, we 
show that the treatment of HLA-A2+/EphA2+ SLR24 cells with B61.Ig significantly increased 
the ability of CL.142 to recognize and react against the tumor cell line.  This suggests that the 
incorporation of EphA2 agonists into combinational immunotherapeutic protocols might prove 
clinically effective in promoting CTL targeting of EphA2+ tumors in vivo.  This might prove 
most compelling in adoptive (CTL) transfer or active vaccination (i.e. EphA2 protein/peptide-
pulsed DC) regimens, where the use of EphA2 agonist would not only be envisioned to inhibit 
the tumorigenicity of EphA2+ cancers, but also to result in increased in vivo recognition of 
EphA2+ tumors by autologous CTLs in patients with active or residual disease.  While 
immunotherapies involving the adoptive transfer of immune cells has been utilized in the clinic, 
with some benefits reported (with several complete responses reported in the setting of 
melanoma, (211), there has not been a great deal of success associated with this single mode of 
therapy.  By combining this approach along with a conditioning regimen making tumor cells 
more easily recognizable by transferred effector T cells, response rates may be improved upon. 
As mentioned previously, EphA2 is constitutively underphosphorylated in the PC3 prostate 
carcinoma cell line.  We explored whether the reversal of the underphosphorylation of EphA2 in 
cancer cells might also result in the restoration of proper EphA2 metabolism and in improved 
CTL recognition of tumor cells.  With reports suggesting that the LMW-PTP is overexpressed in 
many cancers, and that this enzyme acts on EphA2 as a substrate, we studied whether or not 
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pharmacologic inhibition of LMW-PTP activity would induce the degradation of EphA2.  
Similarly, nitric oxide (NO) metabolites have been reported to irreversibly inhibit LMW-PTP.  
The addition of NO-PAPA, a nucleophilic salt that releases NO into media, was able to induce 
EphA2 degradation in a dose-dependent manner.  Of major interest, EphA2 was not the only 
RTK affected by NO-PAPA.  Axl, another RTK implicated in carcinogenesis, was also induced 
(within hours) to degrade by the addition of NO-PAPA to tumor cell cultures. 
Based on our previous results using EphA2 agonists to induce EphA2 degradation, we next 
evaluated whether or not a combinatorial treatment of tumor cells with both and EphA2 agonist 
along with a LMW-PTP inhibitor (i.e. NO-PAPA) would lead to additive synergistic degradation 
of EphA2 protein in treated tumor cells.  As assessed by Western blot, we found that the addition 
of mAb208 in conjunction with NO-PAPA was more efficient in inducing EphA2 degradation 
than either single modality treatment (p =.015).  This supports the possibility of using both 
EphA2 agonist induction and phosphatase inhibitors as a bimodal treatment for EphA2+ tumors.  
As interesting as these findings were, the effects of NO are known to be rather pleiotropic, so we 
wished to further clarify that specific inhibition of phosphatases was responsible for the 
induction of EphA2 degradation that we had observed. 
We approached this by performing analogous experiments using additional, more-refined 
phosphatase inhibitors (e.g. sodium orthovanadate, protein tyrosine phosphatase inhibitor-2).  
We observed that while different phosphatase inhibitors worked better than others, they were 
each capable of inducing the degradation of EphA2 protein in treated tumor cell lines in vitro.  
Interestingly, these treatments also coordinately induced the degradation of two additional RTKs, 
Axl and EGFR (erb-B1).  We further showed that protein tyrosine phosphatase inhibitor-2 (PTP 
I-2) treatment led to a dramatic upregulation of EphA2 phosphorylation.  These findings confirm 
 91
that a lack of tyrosine phosphorylation is a major mechanism underlying tumor cell 
overexpression of EphA2 protein.  This is most likely due to overexpression or overactivity of 
cellular PTPs in EphA2+ tumors, a theory that we are currently evaluating in our laboratory.  We 
believe that the dysregulation of EphA2 phosphorylation represents a major mechanism of 
EphA2 overexpression (Fig. 24). 
With PTP inhibition resulting in the degradation of EphA2 protein in EphA2+ tumors, we 
are currently exploring the possibility that this treatment may enhance the recognition of 
EphA2+ tumors by CTL, similar to our results using EphA2 agonists.  In addition to CTL 
studies, the role of CD4+ T cell should also be explored, since we observed some degree of 
suppression in EphA2 triggered degradation by chloroquine.  The ability of chloroquine, a 
known inhibitor of phago/lyzosome fusion, to inhibit EphA2 degradation suggests that EphA2 
processing may also occur within the MHC class II biosynthetic pathway, with peptides targeted 
into HLA Class II antigen complexes.  Theoretically, this would results in an increase of HLA 
Class II presented EphA2 epitopes, and ultimate presentation to, and reactivity by, specific CD4+ 
T cells. 
A major hurdle to overcome in the possible clinical application of PTP inhibitors is dosing 
and toxicity.  Although RTK degradation is a consequence of PTP inhibition, other antigen 
processing proteins/complexes may also be negatively affected (e.g. proteasome, TAP) which 
could limit the generation and presentation of HLA complexes containing EphA2 epitopes, and 
consequently improved immunoreactivity to treated tumor cells.  We also note that PTP 
inhibitors display increased toxicity over time, providing a potentially substantial obstacle in the 
clinical translation of these PTP inhibitor-based studies. 
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Having said this, there are several PTP inhibitors (e.g. orthovanadate and nitroprusside) 
currently being employed in clinical applications, in the setting of hypertension.  We have 
reported here that orthovanadate induces the degradation of several RTKs, including EphA2, and 
believe the nitroprusside will have a similar effect.  Interestingly, many clinically-used dyes have 
also been reported to serve as PTP inhibitors (212).  For example, Evans Blue, commonly used 
for sentinel node biopsies in cancer patients, is a potent inhibitor of PTP-1B and YPTP1.  These 
compounds could be readily applied in combinational approaches to induce RTK degradation 
and enhanced immune recognition in the cancer setting. 
A potential preferred approach to circumventing the possible detrimental affects of 
previously-applied PTP inhibitors, however, is the use of RNA inhibition (RNAi) to tactically 
“knock out” specific PTPs implicated in EphA2 dysregulation.  RNAi involves using dsRNA 
specific for a given protein to inhibit the translation of the target gene by inducing the destruction 
of the specific mRNA.  This approach allows for the specific targeting of PTPs without the 
deleterious pleiotropic effects of conventional pharmacologic PTP inhibitors.  RNAi targeting 
PTP-1B is currently being used clinically for the treatment of Type-2 diabetes, and should be 
considered for implementation in cancer clinical trials in the near future. 
Not only could RNAi limit the potential harmful side effects of PTP inhibitors, they could 
also be used to specifically establish which PTPs are dominantly involved in tumor cell 
overexpression of EphA2 protein.  As mentioned previously, LMW-PTP is reported to use 
EphA2 as a substrate, making it a prime candidate for RNAi studies.  However, additional PTPs 
have also been reported to be involved in carcinogenesis (204, 205, 207).  
The work performed in this thesis has defined a novel tumor antigen, EphA2, which is 
overexpressed in numerous cancer cell types of epithelial origin (i.e. carcinomas).  The EphA2 
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protein contains epitopes that are recognized by T-lymphocytes and appear therapeutically-
relevant.  Our results demonstrate the ability to target EphA2 for conditional degradation, 
leading to improved recognition by specific CTLs allows for development of novel 
immunotherapeutic approaches that may be applied to numerous types of cancer.  Combined 
with our findings that (PTP) phosphatase inhibitors also induce the degradation of EphA2, this 
thesis introduces the possibility of using a combinatorial therapeutic approach for the treatment 
of EphA2+ tumors.  Along with reports illustrating the efficacy of several other monoclonal 
antibodies used clinically for the treatment of other tumors (e.g. Herceptin, Erbitux), this type of 
therapy could be effective against a wide range of tumor types, and would not be restricted to a 
patients HLA type (as would be the case for peptide-based vaccines).  This therapy would not 
only enhance CTL recognition of EphA2+ tumors, it would possibly also inhibit tumor 
neoangiogenesis and limit the ability of tumors to metastasize.  There are a plethora of RTKs that 
appear to be overexpressed in a broad range of cancer histologies, and given the availability of 
PTP inhibitors and specific agonist anti-RTK monoclonal antibodies, these results may support a 
general combinational therapy platform for the majority of cancers. 
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RTK Overexpressed in cancer? Reference
EphA2 melanoma, breast, colon, lung, pancreatic, prostate 34,55, 56, 59, 143, 148
Axl breast, lung, esophageal, 40, 41
EGFR/erb1 colorectal, breast, ovarian, prostate 42-45
Her2/neu breast, lung, prostate, cervical, 42, 46-48
PDGFR brain, breast 53, 54
KIT colorectal, RCC, ovarian, breast 49-52  
 
 
 
 
Table 1.  RTK and Overexpression in Cancer 
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 Table 2.  RCC Patient Characteristics 
 
Table 1. RCC Patient Characteristics. 
   Date  Date      Survival  Disease Staging: Tumor 
Patient  Sex Age*  Treated  Recurred DFI (Yrs) (Yrs)  T Grade Size (cm3) 
 
1 M 64 1-21-86  3-5-87    1.1  3.0  3B NG 322 
2 M 63 3-11-86  3-6-91    5.0  6.5  1 NG NA 
3 M 59 4-25-86  5-28-87    1.1  1.1  2 NG 560 
4 M 56 2-2-87  2-27-00  13.0  13.0  3a NG 4 
5 M 50 3-26-87  1-3-90    2.7  7.5  3b NG 269 
6 M 71 4-1-87  11-4-91    4.6  11.9  3b NG 180 
7 F 65 4-20-87  NED  16.8  16.8  3b NG 14 
8 F 59 5-21-87  7-13-90    3.2  4.0  3a NG  864 
9 M 68 6-18-87  NED  16.7  16.7  1 NG 14 
10 M 52 12-21-87 NED  16.3  16.3  2 NG 434 
11 F 74 2-10-88  9-15-92    4.6  5.2  1 NG 8 
12 M 48 2-24-88  9-10-91    3.5  8.3  1 II 113 
13 M 51 8-8-88  4-24-89    0.7  4.3  1 NG NA 
14 M 87 8-10-88  9-25-90    2.1  6.1  2 NG 158 
15 M 40 9-1-88  NED  15.4  15.4  4 III 66 
16 M 37 9-28-88  NED  15.3  15.3  1 NG 87 
17 F 52 11-21-88 11-29-90   2.1  2.1  2 IV 288 
18 M 45 3-5-89  5-5-93    4.2  6.2  2 IV 383 
19 M 61 4-21-89  8-18-89    0.3  0.7  3B IV 384 
20 F 63 11-27-89 10-19-90   0.9  1.3  2 III 168 
21 M 58 1-22-90  11-15-95   5.8  11.5  3b II NA 
22 F 55 3-20-90  10-18-90   0.6  1.3  2 IV 270 
23 F 57 3-26-90  8-2-93    3.3  3.5  2 II NA 
24 M 46 5-1-90  7-23-91    1.2  14.0  1 II NA 
25 M 65 7-5-90  8-1-90    0.1  8.8  1 IV 36 
26 M 54 12-5-90  NED  13.2  13.2  3a NG NA 
27 F 50 2-1-91  9-29-93    2.7  12.2  1 II NA 
28 M 58 4-19-91  6-28-91    0.2  2.4  2 III 525. 
29 F 69 8-28-91  9-20-91    0.1  0.3  3b IV NA 
30 F 76 5-14-92  9-14-92    0.3  8.0  1 II 16 
31 F 50 6-1-93  11-29-93   0.5  3.9  3b II 19 
32 M 66 4-19-94  6-13-96    2.2  6.7  2 III 525 
33 M 56 6-28-95  7-18-96    1.1  9.0  3a II 34 
34 M 55 11-27-95 8-20-96    0.8  4.0  3b III 6916 
 
All patients were diagnosed with clear cell RCC with N0, M-. *Patient’s age at the time of tumor resection.  Abbreviations: 
DFI = Disease-free interval; NA = Not available; NG = Not graded; NED = No evidence of disease.  
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Table 3  HLA-A2 and/or DR4 positive RCC patients evaluated in this study.    
  
 Disease status at                               Tumor 
RCC                                   time of evaluation  HLA Typing:               Expression 
Patient      Age    Sex    Stage   Treatment     (Months)   A2 (+/-)/DR4 (+/-) EphA2   
SLR30-pre      63      F     I       none          Local Dis.            +          - NA 
SLR31      66      M     I     S           Local Dis.            +          -    2+ 
SLR32      62      F       I     S           Local Dis.           +               - 2+ 
SLR33       54      F      I  S          Local Dis            +            - 3+ 
SLR34      71      M    I     none          Local Dis.            +          + NA 
SLR35      75      F         I     none          Local Dis.            +          + NA 
SLR36-pre       60      M      I    none          Local Dis.            +          + NA 
SLR37      52      M      I    none          Local Dis.           +           - NA 
SLR38-pre      69      M     I      none           Local Dis.           +          -  NA 
SLR39      65      M     I     S                NED (3)           +           - 3+ 
SLR30-post     63      F      I     S                NED (1.5)           +           - NA 
SLR40      53      M      I      S                NED (3)            +          - NA         
             
SLR36-post     60      M     I      S                NED (2)           +          + NA 
SLR41     64      F      I      S                NED(2)           +          - 2+ 
SLR38-post    69      M      I      S                NED (2)          +          -     3+ 
SLR42      58      F      I      S                Local Dis. (3)      +          -            3+   
SLR43      53      F         I    S                Local Dis. (1.5)      +          - 3+ 
SLR44-pre      69      M   IV     none           Mets.               +          - NA 
SLR45      65      M     IV     S   Mets                +          -  4+ 
SLR46      45      F     IV     S           Mets                +          - 0 
SLR47      53      F      IV    S                 NED (1.5)            +                     -            NA 
SLR48      54      M     IV     S                 Mets. (61)          +                     -            NA 
SLR49      52      F    IV    S, R, IFN-α, Mets. (41)          +          - 2+ 
   IL-2 
SLR44-post     69      M     IV    S                  Mets (2)            +                     -            4+ 
SLR50      54      M    IV    S,R,C             Mets (21)         +                     -            NA 
SLR51      41      M     IV     S,R,IL-2         Mets                +                     + NA 
SLR52      58      M     IV    S,R,IFN-α      Mets                +                     + NA 
SLR53      52      M      IV     S              Mets               +                     - NA 
SLR54      49      F      IV     C,IL-2            Mets                +                     +           NA 
SLR55      79      M     IV     C,IFN-α          Mets                +                     + NA 
SLR56      56      M     IV     R,C,IFN-α,    Mets               +            - NA 
   IL-2  
SLR57      68      F      IV     S            Mets                +                     - 3+ 
SLR58      55      F     IV     none             Mets                +                    + NA 
SLR59      52      F     I      none            Local Dis.            -                     + NA 
SLR60-pre      58      M    I      none            Local Dis.           -                      + NA 
SLR61      60      M     I      S             Local Dis.            -                       + 2+ 
SLR62      64      M    I     S               NED (3)           -                      + NA 
SLR63      53      F      I      S               NED (1.5)            -                      + NA 
SLR60-post      58      M    I      S                NED ( 2)          -                      + NA 
SLR64      65      M    I      S                NED (10)          -                     + NA 
SLR65      53      M    II     S                Local Dis.           -                      + NA 
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SLR66        45      M     IV    none             Mets.                -                      + NA 
SLR67      57      M     IV    C,R              Mets               -                      + NA 
SLR68      69      M     IV     S,R,C            Mets               -           + NA 
SLR69       49      M         IV    S,C,R,IFNα,      Mets                            -           + NA 
            IL-2 
   
 
 
Individual SLR designations reflect specimen number based on date harvested.  In 5 cases, both pre- and 
(6 weeks) post-therapy blood specimens were available for analysis, as indicated.  Where indicated, the 
time of peripheral blood isolation (in months) post-therapy is provided.  Abbreviations used: C, 
Chemotherapy; IFN-α, recombinant Interferon-alpha therapy; IL-2, recombinant Interleukin-2 therapy; 
Mets, Metastatic Disease; NA, Not available for evaluation; NED, No evidence of disease; R, 
Radiotherapy; S, Surgery.  HLA-A2 and -DR4 status was determined using allele-specific monoclonal 
antibodies and flow cytometry gating on peripheral blood monocytes, as described in Materials and 
Methods.  IHC stained tumor biopsies were available from 14 patients and were stained for EphA2 
expression as outlined in Materials and Methods.  EphA2 expression is indicated on an arbitrary 0 to 4+ 
scale.    
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 Table 4.   Selection of EphA2 Peptides for Analysis. 
 
Selected HLA-A2 Presented EphA2 Peptides: 
  Peptide  Peptide  
Sequence Start  AA Sequence Binding  Generated By Synthesized 
Amino Acid # of  Nonamer Score* Proteasome For Analysis  
883 TLADFDPRV 1084          YES  YES 
546 VLLLVLAGV 1006   YES  YES 
550 VLAGVGFFI   556 NO  NO 
58 IMNDMPIYM   138 NO  NO 
961 SLLGLKDQV   127 YES  YES 
253 WLVPIGQCL     98 NO  NO 
12 LLWGCALAA     71 NO  NO 
391 GLTRTSVTV     70 YES  YES 
120 NLYYAESDL     68 NO  NO 
162 KLNVEERSV     49 YES  YES 
 
Selected HLA-DR4 Presented EphA2 Peptides: 
Sequence Start AA Sequence Binding  Peptide Synthesized 
Core AA# of Nonamer Core Score* For In Vitro Analysis 
666 IMGQFSHHN 577  6 6 3EAGIMGQFSHHNIIR6 7 7  
67 YSVCNVMSG   95  6 3PIYMYSVCNVMSG7 5  
55 MQNIMNDMP   39  5 3DLMQNIMNDMPIYMYS6 8  
 
*The higher the binding score,  the greater the stabili ty of  the predicted peptide-MHC 
complex.   Binding scores and quali tat ive determination of proteasomal processing 
were predicted using on-line algori thms as described in Materials and Methods. 
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Table 5.  Normal donor T cell responses to putative EphA2-derived peptide epitopes. 
HLA-A2-Presented EphA2 Peptides :  
 CD8+ T Cell  Response to Peptide on T2.DR4a: 
                                 (IFN-γ  Spots/105 CD8+ T Cells)    
Normal Donor # 162 391 546 883 961 
 A2-1     9    0b  31    0    2    
 A2-2    40 81 14   85 21   
 A2-3     3  14 10    0  21   
 A2-4     2    0  11   58   0    
 A2-5    11   0  14 172   4    
 A2-6     0  91 76 145 13 
 A2-7  132   0    0    37   0 
 A2-8    15   0    0  165   0 
_________________________________________________ 
Total  Responses:  5/8 3/8 6/8 6/8 3/8 
 
HLA-DR4-Presented EphA2 Peptides:  
  CD4+ T Cell  Response to Peptide on T2.DR4a: 
   (IFN-γ  Spots/105 CD4+ T Cells)  
 Normal Donor # 53    63  663 
  DR4-1  43    11  21   
  DR4-2  38    36  57 
  DR4-3   4     7   14 
  DR4-4   0     0    0 
  DR4-5   0  156  41 
  DR4-6   0  121  67 
  DR4-7  54   48  72 
 _________________________________________________ 
Total  Responses:  3/7  6/7  6/7  
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Responder CD4+ or CD8+ T cells were analyzed for reactivity against the HLA-
A2+/DR4+ target cell line T2.DR4 pulsed with no peptides, or pulsed with irrelevant or EphA2-
derived peptides.  T cell reactivity against T2.DR4 cells pulsed with the HLA-A2-presented 
HIV-nef190-198 epitope served as the CD8+ T cell negative control, while HLA-DR4-presented 
Malarial circumsporozooite (CS)326-345  epitope served as the CD4+ T cell negative control.  
These control values were subtracted from experimental determinations in order to determine 
EphA2-specific T cell responder spot numbersa per 100,000 T cells. bA value of “0” reflects a 
frequency < 1/100,000 T cells.  The appropriate HLA-A2 or –DR4 restricted nature of specific T 
cell recognition of peptides was validated by inclusion of anti-HLA-A2 or -DR4 mAb in 
replicate ELISPOT wells, respectively, with >90% inhibition of EphA2-specific recognition 
observed (data not shown).  Values significantly (p< 0.05) elevated over T2.DR4 + control 
peptide values are underlined. 
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Table 6.  EphA2 Agonists Do Not Inhibit MHC Class I or CD40 Expression on SLR24 
tumor cells. 
The SLR24 RCC cell line was either not treated or treated with MG132 (50 µM) and/or mAb208 
(10 µg/ml) as outlined in the legend to Figure 3.  Treated cells were then analyzed for expression 
of MHC class I and CD40 molecules by flow cytometry as described in Materials and Methods.  
Data presented is the mean fluorescence intensity of expression for the indicated markers. 
 
 
 
Mean Fluorescence Intensity: 
Treatment  MG-132 (+/-)  Control   W6/32    CD40 
Untreated  -   0.5   124.7   14.8 
“   +   0.6   127.4   16.6 
mAb208  -   5.5   116.5   19.8 
“   +   7.2   123.7   20.9 
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Table 7.  ED50 Dosage of Pharmacologic Inhibitors.   
The indicated pharmacologic PTP inhibitors were assessed for their ability to induced EphA2 
degradation.  The dosage required for 50% reduction in EphA2 protein content (after 6h 
treatment) is indicated below. 
 
 
 P.I. ED[50]
NO-PAPA 2mg/ml
Sodium Orthovanadate 100mM
PTP Inhibitor-2 100µM
Levamisole 500µM
Phenylarsine Oxide 1µM
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Figure 1.  Schematic Diagram of EphA receptor protein structure. 
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Figure 2.  Schematic Diagram of EphA2 Normal Metabolism. 
MTV – multi-tubular vesicle.  EV – endosomal vesicle.  LYS – lysosome. 
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Figure 3.  Immunohistochemical analysis of RCC Specimens.   
Resected tumor and adjacent normal kidney were obtained from RCC patients #19 (panels A-D) 
and #16 (panels E-H) and stained using anti-EphA2 (panels A, C, E, G) or control IgG (panels B, 
D, F, H) Abs, as outlined in Materials and Methods.  Depicted images were prepared under 40X 
magnification. 
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Figure 4.  Relative EphA2 expression is higher in larger, more vascularized RCC lesions.   
In panel A, the relative tumor expression of EphA2 was determined (as outlined in Materials and 
Methods) and plotted against the calculated volume of the resected RCC lesion (Table 1).  
Sequential tissue sections were also stained with anti-Factor VIII antibodies in order to assess the 
number of tumor blood vessels, with the relative level of vascularity then plotted against EphA2 
expression level in panel B.  Each symbol within a panel reflects an individual patient evaluated. 
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Figure 5. Relative EphA2 expression in resected RCC is prognostic of disease-free interval 
in surgically-cured patients.   
The relative tumor expression of EphA2 was determined (as outlined in Materials and Methods) 
for each patient and the data plotted based on the disease-free interval observed for that patient 
(i.e. < 1 year (n = 10), between 1 and 5 years (n = 13), or > 5 years (n = 11)) after curative 
surgery. Each symbol within a panel reflects an individual patient evaluated.  *p = 0.0003, **p = 
0.001, NS = not significant. 
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Figure 6.  EphA2 is frequently overexpressed in renal cell carcinoma (RCC) cell lines and RCC lesions. 
Anti-EphA2 and control anti-β-actin antibodies were used in performing Western Blot analyses of lysates generated 
from the indicated RCC cell lines, the normal kidney tubular epithelial cell line HK2 and normal peripheral blood 
lymphocytes (negative control), panel A.  Primary and metastatic clear cell RCC lines were assessed as indicated.  
The PC3 prostate cell line and normal donor PBLs served as positive and negative controls, respectively.  
Densitometry levels of EphA2 expression (normalized to β-actin levels) are indicated in parentheses and are 
reported relative to HK2 expression of EphA2 assigned an arbitrary value of 1.  In panel B, primary (Patient SLR33; 
panels a and b) and metastatic (Patient SLR45; panels c and d) RCC paraffin-embedded tissue sections were stained 
using anti-EphA2 antibody (Ab 208; panels a and c) or isotype control antibody (panels b and d) in 
immunohistochemical analyses (40X magnification). 
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Figure 7.  Anti-EphA2 T cells recognize HLA-matched, EphA2+ RCC tumor cell lines.   
CD8+ and CD4+ T cell lines were expanded from normal HLA-A2+ or –DR4+ donors using in 
vitro stimulations with specific EphA2 peptides and evaluated for reactivity against HLA-
matched, EphA2+ tumor target cell lines in IFN-γ ELISPOT assays.  Depicted are examples of 
data generated from a CD8+ T cell clone reactive against the EphA2883-891 epitope (panel A) and 
a bulk CD4+ T cell line after 3 rounds of in vitro stimulation with the EphA2663-677 epitope 
(panel B).  Target cells included HLA-A2+/DR4+ T2.DR4 cells pulsed with irrelevant (HIV-nef 
or Malarial CS) or relevant EphA2-derived peptides, the HLA-A2+/EphA2+ RCC line SLR24, 
the HLA-DR4-negative/EphA2+ PC3 cell line and the HLA-DR4+/EphA2+ PC3.DR4 tumor cell 
line.  The HLA-A2 restricted nature of 883cl.142 reactivity to tumor cell line targets was 
validated by inclusion of the blocking anti-HLA-A2 mAb BB7.2.   Data are reported as spots per 
10,000 (panel A) or 100,000 (panel B) T cells analyzed, are based on the mean +/- SD of 
triplicate determinations and are reflective of at least 3 independent experiments in all cases. 
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Figure 8.  IFN-γ ELISPOT analyses of RCC patient CD8+ T cell responses to EphA2-
derived epitopes versus disease status.   
Peripheral blood CD8+ T cells were isolated from HLA-A2+ normal donors or patients with 
RCC and stimulated with immature, autologous dendritic cells pre-pulsed with the individual 
EphA2-derived epitopes, as outlined in Materials and Methods.  After one week, responder T 
cells were analyzed in IFN-γ ELISPOT assays for reactivity against T2.DR4 (HLA-A2+) cells 
pulsed with the indicated EphA2 epitope.  Data are reported as IFN-γ spots/100,000 CD8+ T 
cells and represent the mean of triplicate determinations.  T cell reactivity against T2.DR4 cells 
pulsed with the HLA-A2-presented HIV-nef190-198 epitope served as the negative control in all 
cases, and this value was subtracted from all experimental determinations in order to determine 
EphA2-specific spot numbers.  Each symbol within a panel represents an individual donor’s 
response to the indicated HLA-A2 presented EphA2 peptides. Abbreviations used: Pre-Op, pre-
operative patients; Post-RD, patients post-therapy (< 21 months) but with residual disease; Post-
LTS, patients post-therapy (> 41 months) with residual disease; Post-NED, patients post-therapy 
with no evidence of disease.  
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Figure 9.  IFN-γ ELISPOT analysis of RCC patient CD8+ T cell responses to EphA2-
derived epitopes versus disease stage.   
Data reported in Figure 8 have been re-plotted as a function of disease-stage.  Abbreviations 
used: AD, patients with active disease; NED, patients with no evidence of disease. 
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Figure 10.  Observed changes in peripheral blood CD8+ T cell responses to EphA2 epitopes 
pre- versus post-surgery in 4 HLA-A2+ patients with RCC.   
Peripheral blood CD8+ T cells were isolated pre- and (6 week) post-surgery from patients with 
RCC, and evaluated for reactivity to EphA2 epitopes in IFN-γ ELISPOT assays, as outlined in 
the Figure 3 legend.  The three Stage I RCC patients (●, ○,τ) were rendered free of disease as a 
result of surgical intervention, while the single Stage IV RCC patient (∇) had residual disease 
after surgery.  Each symbol within a panel represents an individual patient’s response. 
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Figure 11.  Disease-stage skewing of functional CD4+ T cell responses to EphA2 Th 
epitopes in HLA-DR4+ RCC patients with active disease.   
Peripheral blood was obtained from 19 HLA-DR4+ patients (Table 1) and CD4+ T cells isolated 
by positive MACSTM-bead selection as described in Materials and Methods.  After a one-week in 
vitro stimulation with EphA2 Th peptide-pulsed, autologous DCs, responder CD4+ T cells were 
evaluated against T2.DR4 cells pulsed with the indicated EphA2 epitopes in IFN-γ and IL-5 
ELISPOT assays.  Data are reported as IFN-γ spots/100,000 CD4+ T cells and represent the 
mean of triplicate determinations.  T cell reactivity against T2.DR4 cells pulsed with the HLA-
DR4-presented Malarial circumsporozooite (CS)326-345  epitope served as the negative control in 
all cases, and this value was subtracted from all experimental determinations in order to 
determine EphA2-specific spot numbers.  Each symbol within a panel represents an individual 
patient’s response. Linear regression lines for Stage I and Stage IV patient data is indicated for 
each peptide. 
 
 
 
 114
 
C
yt
ok
in
e 
Sp
ot
s/
10
0,
00
0 
C
D
4+
 T
 C
el
ls
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
IFN-γ 
IL-5
Ratio Th1/Th2 
EphA253-68 EphA263-75 EphA2663-677
 
 
Figure 12.  Therapy-associated enhancement of Th1-type, and reduction in Th2-type, 
CD4+ T cell responses to EphA2 in an HLA-A2+/DR4+ patient with Stage I RCC. 
Pre- and post-surgery peripheral blood was available for a single RCC patient with Stage I 
disease.  CD4+ T cells were isolated and analyzed for reactivity to EphA2 Th epitopes, as 
outlined in the Figure 5 legend.  A statistically-significant increase in Th1-type (IFN-γ) and 
decrease in Th2-type (IL-5) CD4+ T cell response post-surgery was noted for the EphA253-68 
epitope.  Therapy-induced changes in CD4+ T cell response to the EphA263-75 epitope were 
similar, with the IFN-γ results approaching a p value of 0.05 and the significant reductions in IL-
5 responses noted (p < 0.001).  T cell responses to the EphA2663-677 epitope pre-/post-surgery 
were not significantly different.  The ratio of Th1/Th2-type responses pre- and post-therapy is 
also indicated for peptides EphA253-68 and EphA263-75.  p values for significant differences are 
indicated. 
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Figure 13. Suppressor CD4+ T cell responses to EphA2 Th epitopes in HLA-DR4+ patients 
with advanced Stage IV RCC.    
Supernatants were harvested from the culture wells of IFN-γ ELISPOT assays and analyzed for 
levels of TGF-β1 using a commercial ELISA kit.  TGF-β1 secretion in response to EphA2 
peptides was only detectable in the supernatants of 3 (of 8 evaluated) patients with Stage IV 
RCC.  The corresponding IFN-γ and IL-5 ELISPOT data for these individual patients’ CD4+ T 
cell responses to EphA2 peptides is also provided.  Each symbol within a panel represents an 
individual patient’s response. 
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Figure 14.  EphA2 Agonists Induce the Phosphorylation of EphA2. 
PC3 (2-4 x 106) cells were treated at the indicated time points (in min) with either B61.Ig (30 
ug/ml) or mAb208 (8 ug/ml).  B61.Ig is a fusion protein consisting of the EphA2 binding domain 
of ephrin-A1 (a major ligand of EphA2) fused to a human Fc region.  Cellular lysates were 
resolved by SDS-PAGE and EphA2 protein was immunoprecipitated using the anti-EphA2 
antibodies D7 in pull-down assays.  Western blot analyses were then performed using anti-
EphA2 and anti-phosphotyrosine antibodies, respectively.  Data are representative of 3 independent 
experiments performed. 
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Figure 15.  EphA2 Agonists Induce the Degradation of EphA2. 
PC3 (A) and SLR24 (B) were treated for 6 hours with either B61.Ig (30 µg/ml) or mAb208 (8 µg/ml) at 
37°C.  Cell lysates were resolved by 12.5% SDS-PAGE and Western blot analyses were performed using 
Anti-EphA2 and control anti-β-actin antibodies.  Anti-Axl antibodies were used to image identically-
prepared lysates as a specificity control in these experiments.  Data are representative of 3 independent 
experiments performed on each tumor cell line. 
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Figure 16.  EphA2 Agonists Induced Degradation is Inhibited by MG132, but not by 
Chloroquine. 
PC3 cells were either treated with B61.Ig (A) or mAb208 (B) as described previously in the 
legend of Figure 1.  MG132 (50µM, Sigma, St. Louis, MO) and Chloroquine (100µM, Sigma, 
St. Louis, MO) were also added to cultures where indicated 30 min. prior to the addition of 
EphA2 agonists and remained in the cultures for the duration of the 24h experiment.  Cell lysates 
were generated and resolved using SDS-PAGE.  Western blot analyses were then performed 
using anti-EphA2 antibodies and negative control anti-β-actin antibodies.  Data are representative 
of 3 independent experiments performed. 
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Figure 17.  EphA2 Agonists Sensitize SLR24 to EphA2-specific HLA-A2 Restricted CTL 
CL.142. 
The anti-EphA2 CTL clone CL142 (148) was analyzed for reactivity against T2 (A2+) cells 
pulsed with the EphA2883-91 peptide epitope and untreated or agonist-triggered HLA-A2+ 
EphA2+ RCC line SLR24 in IFN-γ ELISPOT assays.  Control target cells include: T2 pulsed 
with HIV-nef190-198 (negative control for peptide specificity) and the PC3 (HLA-A2- EphA2+) 
prostate carcinoma cell line.  B61.Ig treatment (30µg/ml) was applied overnight to ensure EphA2 
degradation and HLA antigen processing and presentation of EphA2 epitopes).  Data are 
reported as IFN-γ specific spots/ 50,000 CL.142 cells and are derived from one representative 
experiment of 3 performed. 
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Figure 18.  NO-PAPA Induces EphA2 Degradation.   
PC3 cells (2-4 x 106) were treated for 6 hr with NO-PAPA at the indicated concentrations 
(mg/ml).  Cells were then lysed, with lysates being resolved by SDS-PAGE.  Western blot 
analyses were then performed using anti-EphA2 and anti-β-actin (control) antibodies.  Data are 
representative of 3 independent experiments performed. 
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Figure 19.  Co-Treatment of tumor cells with NO-PAPA and mAb 208 promote enhanced 
EphA2 degradation. 
PC3 cells (2-4 x 106) were treated for 6 hr with either NO-PAPA (Lane 4, 2mg/ml), mAb208 
(Chapter 4, Lane 3, 8ug/ml) or both (Lane 2).  Cells were then lysed, with lysates being 
resolved by SDS-PAGE.  Western blot analyses were then performed using anti-EphA2, anti-Axl 
antibodies and anti-β-actin antibodies.  Data are representative of 3 independent experiments 
performed. 
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Figure 20.  Protein Tyrosine Phosphatase Inhibitor-2 (PTP I-2) Promotes EphA2 
Phosphorylation. 
PC3 cells (2-4 x 106) were treated at the indicated time points with PTP I-2 (100uM).  Cells were 
then lysed, with lysates being resolved by SDS-PAGE.  EphA2 protein was immunoprecipitated 
using the anti-EphA2 antibodies D7 in pull-down assays.  Western blot analysis was then 
performed using anti-EphA2 and anti-phosphotyrosine antibodies, respectively.  Data are 
representative of 3 independent experiments performed. 
 123
EphA2
β-actin
A
β-actin
Axl
B
C
EGFR
β-actin
Ø SOV   PTP I-2
Ø SOV   PTP I-2
Ø SOV Ø PTP I-2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.  Pharmacologic PTP inhibitors Induced the Degradation of Multiple RTKs. 
PC3 cells (2-4 x 106) were treated for 6 hr with PTP I-2 (100µM) and SOV (100mM), 
respectively.  Cells were then lysed, with lysates being resolved by SDS-PAGE.  Western blot 
analyses were then performed using anti-EphA2, anti-Axl, or anti-EGFR antibodies, 
respectively.  Anti-β-actin blotting was performed as a control.  Data are representative of 3 
independent experiments performed. 
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Figure 22.  Unlike PTP inhibitors, Okadaic Acid Does Not Modulate EphA2 Degradation in 
the PC3 Cell Line. 
PC3 cells (2-4 x 106) were treated for 6 hr with OKA at the indicated concentrations.  Cells were 
then lysed, with lysates being resolved by SDS-PAGE.  Western blot analyses were then 
performed using anti-EphA2 and anti-β-actin antibodies.  Data are representative of 3 
independent experiments performed. 
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Figure 23.  Lactacystin and Chloroquine Inhibit PTP I-2 Induced EphA2 Degradation. 
PC3 cells (2-4 x 106) were treated for 6 hr with PTP I-2 (100uM).  Certain groups were pre-
treated for 30min with lactacystin (20uM, Sigma, St. Louis, MO) or chloroquine (100uM, Sigma, 
St. Louis, MO).  Cells were then lysed, with lysates being resolved by SDS-PAGE.  Western blot 
analyses were then performed using anti-EphA2 and anti-β-actin antibodies.  Data are 
representative of 3 independent experiments performed. 
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Figure 24.  Proposed Mechanism of EphA2 Overexpression. 
Overexpression of protein tyrosine phosphatases (PTP) represents a major mechanism of EphA2 
overexpression in cancer.  This can be reversed by the addition of EphA2 agonist and/or PTP 
inhibitors which restore the effects of proper phosphorylation of EphA2 which ultimately leads 
to its proteolytic destruction.  This results in the increased recognition by EphA2-specific CTL, 
which is a proteasome dependent process as the effects of both treatments can be inhibited using 
proteasome inhibitors (e.g. lactacystin, MG132).  EphA2 degradation via PTP inhibitors can be 
inhibited using chloroquine as well; potentially leading an increase in peptides presented on 
MHC Class II molecules for presentation to CD4+ T cells, in EphA2+, MHC Class II+ tumors.  
MTV – multi-tubular vesicle.  EV – endosomal vesicle.  LYS – lysosome. 
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APPENDIX A 
 
 
 
C225 Agonist Addition Induces EGFR Degradation 
 
 
Purpose – Similar to our results demonstrating the induction of EphA2 upon agonist 
administration (Chapter 4), we tested whether the addition of C225, a mAb for EGFR1, could 
induce the degradation of EGF-R (erbB-1). 
 
Methods --  PC3 cells were treated as previously described (Chapter 4) using 10ug/ml C225.  
Cells were lysed after 6 hr and lysates were resolved via SDS-PAGE.  EGFR1 protein was 
assayed by Western blot and detected using anti-EGFR antibodies. 
 
Results – Similar to mAb208’s effects on EphA2, the addition of C225 (10µg/ml) was able to 
induce the degradation of EGFR1.  This affect was inhibited with MG132, confirming the 
proteasome dependency of this process (data not shown). 
 
Conclusions – Combined with our results in Chapter 4, these findings demonstrate the 
generality of the ability induce RTK degradation using agonists and PTP inhibitors. 
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